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Abstract  
The Health Transition Fund report (Kennedy & Goyer, 2002) indicated that prescribing 
practices for benzodiazepines (BZDs) are frequently inappropriate, but more difficult to 
influence than others. The inappropriate benzodiazepine (BZD) prescriptions and the 
inability to influence prescription behavior through educational means provides 
justification for further study to understand the underlying factors associated with 
prescriptions. A survey of physicians can help objectify the variable(s) that play role(s) in 
the prescription of BZDs. For this thesis, a self-administered cross-sectional survey was 
conducted among the physicians in Newfoundland and Labrador in 2007 to assess the 
prescribing patterns of BZDs and variables influencing them. Response rate was 30.68% 
(n= 297) of which 78.48% (n = 233) prescribed BZDs. The BZD prescribing patterns and 
factors affecting them were significantly influenced by demographic variables of the 
respondents; these findings may be used to develop physician education tools that may 
help to optimize the BZD prescribing patterns. 
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Chapter 1: Background:  
The increase in the prevalence of benzodiazepine (BZD) usage coincided with the decline 
of barbiturate use in the 1960s. Since then, there has been a steady increase in the 
prevalence of BZD prescriptions (Lader, 1991). This was perhaps as clinicians 
considered (and still consider) benzodiazepines (BZDs) to be the clinically safe 
alternative to barbiturates, which were until then the choice of sedative-hypnotic agents 
for sleep disorders.  
BZDs have a wide range of actions (anxiolytic, hypnotic, anticonvulsant, amnestic, and 
myorelaxant) which correspond to their clinical uses. As is the case with many drugs, 
they have adverse effects (tolerance, dependence, etc.) which occur from their acute and 
chronic use.  
The World Health Organization (WHO) (1996) in its “Programme on Substance Abuse-
Rational Use of  BZDs” specified the following concerns regarding BZDs: their higher 
prevalence of use in women and the elderly, their role in poly-pharmacy (in conjunction 
with other medication), and their being prescribed outside the accepted guidelines. These 
initial concerns are further augmented by the findings of a recent cross-sectional 
European study  among the general population, which reported that female gender, lower 
education, and higher age predicted the increased use of BZDs (Demyttenaere et al.,  
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2008). The risk/benefit ratio of BZDs become less favorable or even adverse as the 
treatment becomes prolonged, in which case the: efficacy wanes and risks accumulate 
(Lader, 1999). Long term use may also give rise to therapeutic tolerance which is 
manifested by the loss of efficacy or by dose escalation to maintain the effects/benefits of 
the drug (American Psychiatric Association or APA, 1990).  
 The Health Transition Fund was created by the Canadian government to implement pilot 
or evaluation studies focused upon health care issues. These studies were carried out 
between 1997 and 2002. The purpose of these studies was to create evidence-based 
information for decision-making as well as policy-implementing bodies. The Health 
Transition Fund report on the pharmaceutical issues (Kennedy & Goyer, 2002) stated that 
BZD prescribing practices are more difficult to influence than others. Additionally, the 
report indicated that current practices of prescribing BZDs are not amenable to change by 
“educational” intervention and in the event that change is desired, more direct methods 
are needed, such as regulation or financial incentives. A database study conducted by the 
School of Pharmacy, Memorial University of Newfoundland (SOP-MUN), 
Newfoundland and Labrador Centre for Health Information (NLCHI), Division of 
Community Health, Memorial University of Newfoundland (DCH-MUN), 
Pharmaceutical Services Division, Department of Health and Community Services 
(DoHCS) and the Newfoundland Pharmaceutical Association (NPA) in 1999 found that  
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two or more BZDs were inappropriately prescribed to 15.7% (Newfoundland and 
Labrador Prescription Drug Program or NLPDP) and 17.6% (non-NLPDP) of seniors. 
Diazepam (a long-acting BZD) was one of the most commonly prescribed inappropriate 
drugs (Newfoundland and Labrador Centre for Applied Health Research or NLCAHR, 
2003).  
The existence of inappropriate prescription behaviour and the inability to control these 
issues through educational means provides justification for the study of the underlying 
factors which influence the BZD prescribing habits of physicians. This thesis investigates 
a broad range of factors associated with the prescribing of BZDs. This was achieved by 
means of a survey of physicians practising in Newfoundland and Labrador to delineate 
the influences of physician characteristics on their prescribing practices. Exploring the 
influence of demographic characteristics such as age, gender, physician specialties, years 
of experience, etc. on BZD prescribing patterns may fill the knowledge gap in relation to 
the mental health issues faced by patients. It may also be instrumental in the development 
of effective strategies that help clinicans provide better health care to their patients. 
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Chapter 2: Literature Review:  
In the following section, I will provide an overview of literature pertaining to BZDs; 
specifically, topics such as epidemiology, pharmacology, and the medical/clinical use of 
BZDs with focus on physician characteristics will be discussed. I will also present the 
recommendations of recognised national and international guidelines on the clinical use 
of BZDs. This section (especially section 2.11) will lay out the scientific reasoning 
behind the inclusion of each parameter in the survey questionnaire presented in this 
thesis. Furthermore, the literature in this section will aide in interpretation of the results 
of the survey and its subsequent discussion (Chapter 4 and 5, respectively). 
2.1 Literature search for overview on BZDs 
The Embase, PubMed, and Cochrane databases were searched for peer reviewed articles 
and reports using the following keyword(s) either in combination or individually: BZD, 
BZDs, physicians, prevalence, survey, (ab)use, consumption, epidemiology, prescrib*, 
prescription, behaviour, attitudes, perception, variables, factors, mechanism of action, 
pharmacokinetics, pharmacodynamics, clinical uses, adverse effects, side effects, seniors, 
elderly, guideline(s). The literature search was limited to articles pertaining to studies on 
human beings. Articles were only included if they were published in the English 
language. Additionally, in Embase, articles were included if any of the search term(s)  
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were the major focus of the publication. Furthermore, books, reference lists at the end of 
each article, Canadian government websites, and websites focused upon the BZD class of 
drugs or its indications were parsed to identify relevant information. 
2.2  Epidemiology of BZD 
Global epidemiology explained  in the context of manufacture, consumption or via sales 
data provides information on the prevalence patterns of BZDs but not on the perceptions 
held by either the prescribers or the consumers of BZDs. Data on the epidemiology of 
BZDs across regions is presented below to help understand variations observed in its 
prevalence (especially in the elderly and in developed nations) in global settings.  
The WHO (1996) in its “Programme on Substance Abuse-Rational Use of BZDs” 
reported that: 1. the sales data of BZDs especially in relation to short-acting drugs 
demonstrated an increase, 2. less than half the number of patients received it for a 
recognized indication, 3. even fewer patients received it for the advised duration, 4. the 
prevalence of BZD usage is higher in women and highest in older populations, and 5. 
older patients filled a higher percentage of BZD prescriptions than younger ones. The 
report also mentions that the countries with the highest volumes of pharmacy sales in 
1989 were, in descending order: the United States, France, Japan, Italy, the United 
Kingdom, the former German Democratic Republic, Spain, Brazil and Canada. As this  
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report was not a meta-analysis of the studies but a review article, it was difficult to 
ascertain the accuracy and limitations of the data. There are wide variations in the 
definitions of BZD use and the observation period. Its prevalence rate can vary from 
2.2% to 17.6%. A Dutch study of a prescription database in a study population of 18-75 
year olds demonstrated prevalence rates from 0.2% (short-term users; period of 
observation: ≤ 30 days) to 8.9% (short- and long-term users; period of observation: 1 
year). The ratio of female: male (2:1) users remained constant irrespective of the 
prevalence rate. In the short-term users, 51.1% were older than 45 years; while in the 
long-term users, 81.7% were 45+. The proportion of 45+ was fairly constant in the long-
term users. In contrast, data concerning short-term users demonstrated that the longer the 
observation period, the lower the proportion of users over 45-years in age (Zandstra et al., 
2002). Furthermore, a recently published retrospective database study on pharmacy 
dispensing habits concluded that 9.1 % of adult Swiss nationals (15 years and older) had 
used BZDs (period of observation: 6 months) in 2002 (Petitjean, Ladewig, Meier, 
Amrein, & Wiesbeck, 2007) and 56% of these patients had prescriptions lasting longer 
than 90 days (defined as long-term use). Long-term BZD prescriptions by physicians 
(more than 30 days) for any indication contradicts the recommendations of the guidelines 
developed in various regions (APA, 1990; WHO, 1996; Cooperstock & Hill, 1982). 
An Australian study observed that a small but clinically significant number of patients  
7 
 
who usually do not take BZDs received them at the time of discharge from a teaching 
hospital. Practices like these may put them at risk of becoming long-term users (Howes,  
Ryan, Fairbrother, O'Neill, & Howes, 1996). Long-term usage of BZDs is observed in 
developed as well as developing nations. According to a 2007 Norwegian study, 11% of 
the patient population (seen by general practitioners) suffered from sleep disorders and 
about one-third of  them were prescribed BZDs for more than 6 months (Sivertsen, 
Nordhus, Bjorvatn, & Pallesen, 2010). The average period of consumption of diazepam 
was found to be 10 years among chronic users in Brazil in 2001 (Ribeiro, Azevedo, Silva, 
& Botega, 2007). Additionally, it was revealed to be the most dispensed psychotropic 
agent in Latvia for 18-89 year olds patients between 2004 and 2007 (Vrublevska, 
Rukmane, Burmistrs, Sipols, & Muceniece, 2008). The prevalence of BZDs for periods 
longer than recommended has been documented from consumption (prescription) records 
and physician perspectives but the rationale behind these actions are not well understood. 
 
In 2000, the International Narcotics Control Board (INCB) released its annual report 
covering the topic of the over-consumption of internationally controlled drugs.  It 
mentioned that ever since the second half of the 1980s, when governments started to 
report to the Board on BZDs, the average per capita consumption of BZDs has been 
much higher in Europe than in any other region. On average, consumption in European 
countries was three times higher than in the United States. The report also mentions that  
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the prevalence of anxiety and insomnia and the consumption of sedative hypnotics were 
growing in the developed countries, with the elderly being the main group of consumers. 
Another indication of growth in consumption of  BZDs by developed nations was 
observed in 2011, with the United States along with Japan and Spain being the largest 
importers of  BZDs (International Narcotics Control Board or INCB, 2012).  
As per the United Nations (2004), the proportion of population in the developed nations 
is ageing at faster rate than in other regions of the globe. The Beers Criteria was updated 
to aid practicing clinicians in prescribing drugs which would ensure better outcomes 
among elderly patients (The American Geriatrics Society 2012, Beers Criteria Update 
Expert Panel, 2012). Long-acting BZDs are not recommended to be prescribed to the 
elderly according to the Beers Criteria. Inappropriate prescribing of long-acting BZDs in 
the elderly population was analyzed to be 5% in Ireland (study population: ≥70 years) 
(Cahir et al., 2010) and Sweden (study population: ≥75 years) (Johnell, Fastbom, Rosén, 
& Leimanis, 2007); 11.4 % in Japan, (study population: ≥65 years) (Akazawa, Imai, 
Igarashi, & Tsutani, 2010) and 21.3% in Taiwan (study of population: ≥65 years) (Lai et 
al., 2009). Studies conducted to analyze BZD use among the elderly showed distinct 
prevalence rates between developed nations such as the United States  (13.7%; study 
population: ≥65 years) (Yang, Simoni-Wastila, Zuckerman, & Stuart, 2008), Austria 
(13.8%; study population: ≥75 years) (Assem-Hilger et al., 2009), and Australia (16%;  
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study population: ≥65 years) (Windle, Elliot, Duszynski, & Moore, 2007) and developing 
countries such as Brazil (21.7%; study population: ≥60 years) (Alvarenga, Loyola Filho,  
Firmo, Lima-Costa, &  Uchoa, 2008). This distinction may be due to the extent of 
coverage for BZDs, access to health care resources, self –medication by patients, and the 
existence and implementation of regulations governing BZD prescriptions in these 
countries. 
 
With respect to the consumption of zopiclone, it was found that state and privately 
insured Germans consumed about 2.7 DID in 2008 (Hoffmann, Hies, & Glaeske, 2010). 
DID is expressed as the defined daily doses per 1,000 inhabitants per day. Zopiclone is 
preferred over BZDs for the management of insomnia in elderly patients (Siriwardena, 
Qureshi, Gibson, Collier, & Latham, 2006). Note that zopiclone along with zaleplon and 
zolpidem are known as ‘z’ drugs or non-BZDs.  
 
In 2012, the INCB published a report in regards to psychotropic substances based on 
statistical data received from various countries for the year 2011.  Following are 
comments of the INCB (2012) with respect to the BZD class of drugs:  
In 1984, Thirty-three BZDs were included in Schedule IV of the scheduling criteria 
adopted by the World Health Organization Expert Committee on Drug Dependence 
(1971 convention). This schedule includes substances with liability to abuse but which  
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pose a smaller, but still significant, risk to public health than substances included in 
Schedule III. Midazolam was added to Schedule IV in 1990 and brotizolam was added to 
it in 1995.The document uses ‘defined daily doses for statistical purposes’ (S-DDD) to  
analyse and report statistical data.  This is proposed to be an approximate figure with a 
‘certain degree of arbitrariness’ and is not the same as recommended dose in clinical 
practice. S-DDD for levels of consumption is calculated per thousand inhabitants per day. 
Some examples of S-DDD are : lorazepam: 2.5mg, diazepam: 10.0mg, clonazepam: 
8.0mg, and midazolam: 20.0mg (INCB, 2012). 
 
Twenty-two,  twelve, and one BZD were generally classified as anxiolytics, sedatives-
hypnotics, and anti-epileptics respectively. Data on the global manufacture and the 
approximate calculated consumption of anxiolytics did not match: global consumption 
level (18.5 billion S-DDD) was below the manufacture levels (19 billion S-DDD) of 
BZD. The level of approximate global consumption (7.7 billion S-DDD) was calculated 
to be more than the global output (manufacture) level (7 billion S-DDD) for sedatives-
hypnotics type of BZDs. One possible explanation for this discrepancy could be an 
underreporting of manufacturing data. In 2011, global manufacture and approximate 
calculated consumption of the anti-epileptic clonazepam was calculated to be 975 million 
S-DDD and 1.01 billion S-DDD respectively. In 2011, Italy was the main manufacturer 
of all types of BZDs, including anxiolytics, sedatives-hypnotics and anti-epileptics. Lack  
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of data on BZD manufacture from countries like India and Brazil, which were also its 
major producers in 2010, may present an incomplete picture on the overall output of 
BZDs across the world.  
 
Within the anxiolytics segment, alprazolam accounted for 36% of the total manufacture 
in 2011, followed by diazepam (27%) and lorazepam (19%). Lormetazepam (23%), 
brotizolam ( 21%), and triazolam (14%) accounted for more than 50% of the 
manufacturing in the segment of BZD sedatives-hypnotics. The United States was the 
largest consumer of anxiolytics such as alprazolam, diazepam and lorazepam, and 
antiepileptics such as clonazepam.  Japan was the largest importer of sedatives-hypnotics 
such as, brotizolam and triazolam, and Spain was the largest consumer of lormetazepam. 
The accuracy of this report relies on voluntary submission of statistical data from the 
governing bodies in each participating state. One hundred and eighty-three out of 196 
states are members of the INCB but not every member is compliant with the data 
submission process. For example: Canada did not report data on the consumption of 
drugs in schedules  III and IV (which include BZDs) for analysis in 2011. Note that ‘z’ 
drugs such zopiclone and zaleplon are omitted in this report.  
Regional variation in approximate BZD consumption was also observed, with anxiolytics 
being most consumed in Oceania and sedatives-hypnotics in Europe. Such variation may  
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be due to the impact of a multiplicity of factors such as health status of the population 
(US Burden of Disease Collaborators, 2013), age- based demographic differences, 
country specific regulatory or legislative laws on drug promotion (Mintzes et al., 2013), 
use of BZDs for different clinical indications and doses, and different prescribing 
practices as per the local clinical practice guidelines (CPG) among other reasons (Smith 
et al., 2008). 
2.3  Epidemiology of BZD use in Canada 
Between 1978-83, Canada had the second-lowest total BZD use among several Western 
countries. Analysis of BZD sales between 1978-87 in Canada, expressed as the defined 
daily dose (DDD) per 1000 inhabitants per day, showed that the use of these drugs was 
stable during the first half of the decade at 33 DDD/1000 inhabitants per day. From 1983 
to 1987, this number steadily increased reaching 48 DDD/1000 inhabitants per day in 
1987. The total use of slowly eliminated BZD declined, whereas the overall use of 
rapidly eliminated BZD increased ( Busto, Lanctôt, Isaac, & Adrian, 1989). Sales of a 
prescription drug does not automatically translate into its consumption (Mehuys et al., 
2012), but  it does provide a snapshot of the prescribing patterns of physicians.  
Along with the steady increase in sales of BZDs, the prevalence of long-term use also 
rose in Canada. In 1989, BZDs were commonly used on a long-term basis, with 66% of 
the study population receiving at least one prescription. Females received substantially  
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more prescriptions than males. In the senior population, 80.8% received at least one 
prescription with triazolam being the most frequently dispensed central nervous system 
(CNS) drug (74 prescriptions per 1000 people) (Quinn, Baker, & Evans, 1992). A decade 
and a half later, women and seniors (aged 65 years and over) featured prominently in 
BZD usage patterns. Also, older age (65 years and over) was associated with long-term 
(more than or equal to 100 days) use of BZDs (Cunningham, Hanley, & Morgan, 2010).  
Therapeutic Letters is a forum targeting therapeutic issues and was developed by the 
Therapeutic Initiative, a British Columbia Ministry of Health funded program. Their 
examination claimed BZD use in British Columbia grew between 1996 and 2002 by 
11%; with 9.7% of the population receiving at least one prescription for a BZD in 2002 
(Therapeutics Initiative, 2004). Given that the study could not be appraised critically due 
to the omission of details such as study methodology, it was difficult to ascertain the 
validity of their findings. However, a peer-reviewed article (comprising of a prescription 
database study) concluded that the BZD prevalence among British Columbians increased 
to 8.4% in 2006 from 7.8% in 1996 (Cunningham et al., 2010). 
Therapeutics Letter further claimed that the seven most used BZDs were lorazepam 
(Ativan®), clonazepam (Clonapam®), zopiclone (Imovane®), oxazepam (Oxpam®), 
alprazolam (Xanax®), diazepam (Valium®) and temazepam (Restoril®). Five out of these 
seven have half-lives >10 hours (Therapeutics Initiative, 2004). A 2003 claims database  
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analyses reported different statistics: 8 different types of BZDs accounted for 90% of the 
prescribed BZDs for seniors (aged 65 years and older) in Nova Scotia with 19% of the 
prescribed BZDs having a long half-life (Smith et al., 2008). A lower percentage of males 
versus females (7.1% and 12.2%, respectively) received a BZD prescription in British 
Columbia (Therapeutics Initiative, 2004). This claim was validated by findings in a study 
by Cunningham et al. (2010) which concluded that more women received BZD 
prescription for long (more than or equal to 100 days) and short (less than 100 days) term 
periods in British Columbia in 2006. 25.4% of the population aged 65 and over in 
Quebec reported using BZDs in 2005-2006 and approximately 9.5 % of them were 
identified as having substance abuse issues (as per DSM-IV-TR criteria) (Voyer , 
Préville, Cohen, Berbiche, &  Béland, 2010). While Cunningham et al. (2010) noticed a 
decrease in BZD prevalence in the elderly (aged 70 years and older), they did observe an 
increase in BZD use in the middle aged (45 to 64 years) cohort. Comparative data 
showed that elderly Nova Scotians (aged 65 years and over) used BZDs twice as much as 
the elderly population in Australia from 2000 through 2003 (Smith et al., 2008).  Though 
the explanation for regional variations in BZD prescribing patterns has not been studied, 
it may be due to factors such as patient demographics, disease epidemiology, access to 
health care etc. Note that the BZD-like drugs, which include zopiclone and zaleplon, 
were included in the data analyses of the following studies: Therapeutics Initiative, 2004; 
Smith et al., 2008; Cunningham et al., 2010.  
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Sales and prescription data demonstrate the prevalence or incidence of a drug in given 
populations. However, they neither elicit physicians’ perspective on medication use nor 
do they examine the factors that influence the prescriber’s decision making process to 
prescribe a drug to patients. In this case, a self reported survey among prescribers is 
critical to elicit such thoughts and perceptions.  
2.4  Epidemiology of BZDs in Newfoundland and Labrador and the barriers faced by 
prescribers 
The prescription of BZDs in the elderly necessitates a cautious and careful approach as 
they are more sensitive to the potential side effects of these drugs on account of the 
altered pharmacokinetics and pharmacodynamics. In an effort to elucidate the prevalence 
of potentially inappropriate medication use in seniors of this province, analyses 
conducted by SOP-MUN, NLCHI, DCH-MUN, DoHCS & NPA reported that 15.7% and 
17.6% of NLPDP and non-NLPDP seniors, respectively, were taking two or more BZDs 
(NLCAHR, 2003). BZDs bind on the same receptor. Hence it is necessary to avoid 
prescribing more than one BZD to the same patients on account of their different 
affinities to these receptors.  
The Health Transition Fund report (Kennedy & Goyer, 2002) reported findings from their 
studies indicating that BZD prescribing practices are more difficult to influence than 
others, while also illustrating that current BZD prescribing practices are not amenable to  
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change by “educational” interventions. This report did not describe the study parameters 
utilized, hence it was difficult to gain insight into its sample population and methodology 
of the interventions used to influence BZD prescribing habits. The report further 
mentioned that if change is desired, other more direct methods are needed, such as 
regulation or financial incentives. This conclusion is contrary to the study findings by 
Hayward, Guyatt, Moore, McKibbon, & Carter, (1997) who found that peer consultation 
was the most cited source of information to make clinical decisions. On the other hand, 
(provincial) insurance plans were the least accessed tool to influence these clinical 
decisions. Additional statements in the Health Transition Fund report (Kennedy & Goyer, 
2002) were that the measured impact on prescribing for BZD in the Elderly project 
(NA221) was disappointing as no changes were seen in Newfoundland, which was also 
confirmed by the findings of the Sleep and Anxiety Management Project (BC201-01). 
More physicians increased rather than decreased their BZD prescribing patterns, in 
relation to number of patients, volume of BZDs, and number of prescriptions (Kennedy 
& Goyer, 2002). An equivocal response was observed in the study by MacCarthy, 
Kallstrom, Kadlec, & Hollander (2012). Though the study by Hayward et al. (1997) 
postulated peer consultation as a factor which influences the practice patterns of 
prescribers, general practitioners reported a decrease (41%) or an increase (20.8%) 
respectively in prescribing medications after attending the peer to peer program 
addressing adult mental health topics (MacCarthy et al., 2012). Implementation of  
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evidence-based medicine gained traction in Canada around the 1990s, but lack of 
prevalence of optimal prescribing habits suggests that such evidence though disseminated 
are not fully embraced by prescribers (Evidence-Based Medicine Working Group, 1992; 
Pimlott et al., 2003). Lack of time and inadequate training acted as impediments to 
Canadian resident surgeons practicing evidence-based medicine (Bhandari et al., 2003).  
Though the practice characteristics of resident surgeons differ from general practitioners’ 
and other specialties including psychiatry, their concern about time contraints was 
identified as a barrier towards the adoption of guidelines by Canadian physicians as well 
(Hayward et al., 1997). Administrative measures such as electronic monitoring via drug 
alerts and integrated prescription systems providing real time access to prescription 
records of patients can reduce inappropriate prescribing to elderly patients aged 65 years 
and older (Dormuth, Miller, Huang, Mamdani, & Juurlink, 2012; Tamblyn et al., 2012). 
Though administrative measures to reduce inappropriate prescriptions are effective, 
modulating prescriber habits remains critical to better overall quality of care for patients. 
Administrative strictures on drug use are overridden when the prescriber decides that the 
benefits outweighs the risks associated with the therapy (Tamblyn et al., 2012); thus gaps 
in prescriber education should be addressed to reduce dissonance between clinical 
evidence and prescribing practice among the elderly. Eliciting views from stakeholders in 
the Canadian health care system may help to gain insights into their perceived barriers,  
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variables of importance, and suggested facilitators to providing optimized patient care. 
Subsequent implementation of multiple interventions targeting health care stakeholders 
may hold the key to the conundrum of resistance to the uptake of evidence-based 
medicine. 
Inappropriate prescriptions and the inability to influence prescription behavior through 
educational means justify a study to understand the underlying factors associated with 
these actions. This type of survey will help to objectify the variable(s) which plays a 
role(s) in the prescription of BZDs.  
 2.5  Mechanism of action of BZDs 
BZDs potentiate the effects of gamma-aminobutyric acid (GABA) by binding to the 
gamma subunit of GABA-A (protein complex) receptors. In contrast to BZDs, GABA 
binds to the alpha subunit of GABA-A receptors. GABA is an inhibitory neurotransmitter 
which is produced in brain. In general GABA influences a calming effect on the brain as 
approximately 40% of the millions of neurons all over the brain respond to GABA.This 
natural action of GABA is augmented by the BZDs which act to enhance the inhibitory 
influence on neurons. GABA binds with its receptors to produce an allosteric or structural 
change. These GABA bound neurons allow a greater than normal amount of choride ions 
to pass to the inside of neuron. This leads to a decrease in the excitability of the said  
19 
 
neurons by other neurotransmitters. The reduction in response by GABA bound neurons 
to the other neurotransmitters causes the ‘quietening effect’ of GABA. BZDs binds at its 
receptors, situated in the protein complex on the outside of the neuron. This complex also 
contains the GABA receptor. It is pertinent to note that BZDs act by binding to a 
different subunit of the receptor i.e. it does not replace GABA at the neuronal receptor as 
the receptor has different binding sites for GABA and BZD, respectively. The 
combination of a BZD at this site potentiates the actions of GABA, allowing more 
chloride ions to enter the neuron and further increasing its unresponsiveness to other 
neurotransmitters. Various subtypes of BZD receptors have slightly different actions. One 
subtype (alpha 1) is responsible for sedative effects, while another (alpha 2) for anti-
anxiety effects. Moreover, both alpha 1 and alpha 2 subtypes, as well as alpha 5, elicit 
anticonvulsant effects. The receptors in specific neuroanatomic areas seem to mediate 
specific clinical effects. Hence, it is likely that receptors in the cerebellum mediate ataxic 
effects, receptors in the brain stem or cortex mediate sedative effects, receptors in the 
hypothalamus mediate neuroendocrine effects (e.g., decreases in adrenocorticotropic 
hormone, increases in growth hormone etc), receptors in the forebrain and hippocampus 
mediate amnesic effects, and receptors in the amygdala, hippocampus and other limbic 
brain areas mediate anti-conflict and anti-anxiety effects. Different proportions of the 
receptors must be occupied to produce different clinical effects ( Roy-Byrne & Cowley, 
1991; Woods, Katz, & Winger, 2000). 
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An indirect effect of both GABA and BZDs is a reduction in the brain's output of 
excitatory neurotransmitters such as  norepinephrine (noradrenaline), serotonin, acetyl 
choline and dopamine. These excitatory neurotransmitters ensure optimal functioning of 
a human body. Furthermore, they are necessary to meet the social, biological and 
physical challenges faced by humans in their daily life. Some of vital functions which are 
affected by the excitatory neurotransmitters include:  normal alertness, memory, muscle 
tone and coordination, emotional responses, endocrine gland secretions, heart rate and 
blood pressure control. Furthermore, there are non-GABA receptors present in the 
kidney, colon, blood cells and adrenal cortex which could be influenced by certain BZDs. 
The adverse effects of BZDs is linked to its dosage and actions on a range of receptors  
(Ashton, 2002). 
2.6  Pharmacokinetics of BZDs 
The clinical effects of BZDs are determined by pharmacokinetic and pharmacodynamic 
factors. The pharmacokinetic profile is an important consideration when prescribing 
multiple doses. It should be noted that it takes five half-lives to attain a steady-state blood 
level and once attained, it takes five half-lives of the drugs to be more than 90% 
eliminated from the body after dosing has been discontinued. 
The onset and duration of action of BZDs are related to the mode of administration, the 
dissolution of the formulation, absorption, uptake in CNS and binding to form the BZD  
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GABA receptor complex (Lader, 1987).  
The absorption of BZDs are rapid and almost complete from gastrointestinal tract. Unlike 
GABA which cannot pass through the blood brain barrier (BBB), BZDs can cross the 
BBB by passive diffusion and reach equilibrium in the CNS. The amount of drug in the 
brain is directly proportional to the unbound concentration in plasma.  
BZDs are divided into two groups with respect to hepatic metabolism:  
1. one which undergoes biotransformation or the Phase I process including mainly  
oxidation and dealkylation, and  
2. Phase II process of  conjugation to form glucuronides, sulfates, and acetylated 
compounds.  
BZDs can undergo both Phase I and Phase II metabolism (diazepam, chlordiazepoxide, 
and flurazepam) or Phase II alone (lorazepam, oxazepam, and temazepam). Drugs 
metabolized via Phase II processes alone are better tolerated than Phase I/Phase II drugs 
by patients with liver impairments, such as alcoholics. Also, Phase I metabolism slows 
with age. Elderly patients taking BZDs which are metabolized via Phase I as well as 
Phase II processes are more likely to experience more adverse effects of these drugs due 
to diminished hepatic biotransformation/elimination. 
Biotransformation produces a number of active metabolites. Each metabolite possess its  
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own kinetic properties with individual clinical profiles (therapeutic and toxic effects). For 
example, chlordiazepoxide has the following clinically active  metabolites: desmethyl 
chlordiazepoxide, demoxepam, desmethyl diazepam and oxazepam; other examples of 
BZDs with active metabolites include diazepam (active metabolites: desmethyl diazepam, 
temazepam, oxazepam), halazepam, clorazepate, and prazepam. Lorazepam, oxazepam 
and temazepam do not undergo Phase I biotransformation and hence do not produce 
active metabolites. 
BZDs which are rapidly cleared from the body are short-acting agents while the long-
acting agents are the ones which remain in the body for a longer duration.  
The elimination half-life is the time taken by the drugs to fall to 50% of the original 
concentration. The active metabolites of these drugs have their own elimination half-life, 
usually ≥30 to 50% longer than the parent compound. It is pertinent to note the relation 
between half-life and dependence, which is one of the adverse effects of BZDs. High 
potency BZDs with short half-life (alprazolam, lorazepam and triazolam) increase the 
risk of dependence (Nelson & Chouinard, 1999). The elimination half-lives of the BZDs 
vary greatly. Lorazepam, oxazepam, temazepam and lormetazepam have half-lives of 
about 6-24 hrs. As most of each dose is eliminated within a relatively short span of time, 
these compounds are suitable for acute, short-lived anxieties and insomnia. Triazolam has 
a half-life of less than four hours which makes it the shortest acting drug in the arsenal of  
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the BZD class of medications. Although flurazepam itself has a short half-life, it has a 
long-acting active metabolite which makes it unsuitable for the management of short 
lived anxiety or insomnia (APA, 1990). 
2.7  Pharmacodynamics of BZDs 
BZDs achieve inhibitory effects by enhancing the effects of GABA. They bind to a 
gamma subunit of the neuronal receptor located in the CNS causing more influx of 
chloride ions into the neuron thereby making it hyperpolarized and less sensitive to 
excitatory neurotransmitters. Much as the pharmacokinetic properties differ among 
individuals, the pharmacodynamics may display large interindividual differences which 
are reflected by variations in BZDs sensitivities and the rate of development of tolerance 
and dependence. The receptor characteristics may be affected by prior use of BZDs, by 
other drugs and by patients’ clinical state (Roy-Byrne & Cowley, 1991). 
2.8  Adverse effects of BZDs 
The population  of seniors (aged 65 years and over) in Newfoundland and Labrador is set 
to reach nearly 20 % of the total provincial population by 2016 (Government of 
Newfoundland and Labrador, 2006). Monitoring the health care of seniors is necessary as 
they are at an increased risk of drug-drug interaction(s) on account of being prescribed 
medications from different therapeutic classes (The American Geriatrics Society 2012  
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Beers Criteria Update Expert Panel, 2012). The survey population (prescribers) described 
in this thesis is expected to continue providing health care to the changing demographics 
of  Newfoundland and Labrador. Understanding the risks and adverse effects associated 
with BZDs will help to better understand the context of this study: elicitation of variables 
associated with BZD prescribing. The following sections elucidate the risk(s) faced by 
the (younger) adult population and seniors who consume BZDs. 
2.8.1 Tolerance, dependence and withdrawal 
The known adverse effects of BZDs, which are physiologic dependence and tolerance, 
are clinical conditions which are related to the pharmacodynamics of these drugs. 
There are two types of dependence: physiologic and psychological. Physiologic 
dependence is generally subsequent to prolonged drug exposure; the exposure time 
required to produce physiologic dependence may vary with different BZDs. This is 
demonstrated by ‘objective’ physiologic alterations when BZDs are stopped.  
Psychological dependence denotes ‘subjective’ experiences of ‘craving for drug’ and an 
‘unpleasant sensation’ when the drug is discontinued. Both, physiologic and 
psychological dependence may coexist (Greenblatt & Shader, 1978). 
 
A variety of parameters are responsible for influencing the modification of the CNS 
functions. Some of the important factors are: drug dose and duration, pharmacological  
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differences in the derivatives, and predisposition of different users. This adjustment to the 
CNS is manifested via dependence. BZDs are classified according to their potency. Since 
high potency BZDs have a greater affinity to receptors, they produce a similar effect at a 
lower dose. High potency BZDs (with short half-life) such as alprazolam, lorazepam and 
triazolam tend to increase risk of dependence (Nelson & Chouinard, 1999). 
Tolerance is manifested by diminished response to drug administration after multiple 
doses and necessary dose escalation in order to achieve the effect of the previous dose. 
Tolerance can be of two types: receptor site tolerance/adaptation, characterised by 
changes in drug-receptor interactions  due to prolonged exposure of the drug (at any 
concentration) to the CNS receptor. The other type of tolerance is metabolic or 
pharmacokinetic tolerance denoting ‘the effect of prolonged drug exposure on its own 
kinetic properties’ (Greenblatt & Shader, 1978).  
Pharmacokinetic variables of BZDs such as rate of absorption, lipophilicity and receptor 
affinity and patient variables influence the rate, extent and time for the onset of tolerance. 
Since long length exposure of the receptor to BZDs facilitates the onset of tolerance, 
prescribing BZDs at a low dose and for short periods of time may help to avoid it (Nelson 
& Chouinard, 1999).   
Withdrawal of a BZD leads to discontinuation symptoms: recurrence, rebound, and  
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withdrawal. Recurrence symptoms are the same as the original symptoms for which a 
BZD was prescribed. They are observed after the BZD is terminated. Rebound symptoms 
are similar to recurrence symptoms, except that they are more intense. Withdrawal 
symptoms are novel symptoms dissimilar from the original ones and are experienced 
after abrupt discontinuation of  a BZD (Nelson & Chouinard, 1999).     
Short-acting BZDs are preferred for managing transient insomnia and short-term anxiety 
amongst others clinical conditions. However, abrupt discontinuation of short and 
intermediate acting BZDs can lead to the emergence of rebound symptoms. Endogenous 
neurobiological compensatory mechanisms are activated to manage the effects of the 
BZD receptor complex. Abrupt withdrawal of any drug produces withdrawal and rebound 
effects on account of the unrelenting compensatory mechanism which readjusts itself to 
the new drug-free situation after a certain time interval. However, when the amount of 
BZD is decreased in a deliberate systematic method, the aforementioned mechanism 
readjusts itself accordingly before finally returning to baseline. Thus, in order to 
eliminate the risks of developing withdrawal or rebound symptoms, guidelines 
recommend against the instant withdrawal of BZDs. Slow tapering off of a BZD after 
switching the patient to a long-acting BZD is the preferred protocol of discontinuation of 
BZDs (Nelson & Chouinard, 1999).   
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2.8.2  Cognitive effects and psychomotor effects 
Acute BZD administration causes sedation, drowsiness, psychomotor slowing, 
anterograde amnesia and difficulties in learning new material while chronic use leads to 
tolerance, impaired visuospatial and visuomotor abilities, decreased intelligence quotient, 
motor coordination, psychomotor speed, speed of information processing, verbal learning 
and concentration. Most of these effects show improvement after discontinuation of the 
therapy, but the improvement never rises to that of non-users of the drug. Hence, patients 
should be advised of the possible cognitive effects before initiating treatment. Verbal 
learning and remembering information gathered after the initiation of BZDs was also 
found to be impaired; though memory of information stored prior to BZD administration 
was not affected (Lader, 1999; Stewart, 2005).  
The ability of BZDs to impair cognition and psychomotor function is important not only 
for the patient’s health but also for the safety of co-workers. Hence, careful prescribing 
should be practiced by taking into account individual personality traits, psychiatric illness 
and lifestyle of the patient, or in workers performing complex psychomotor functions 
such as driving, handling machinery, etc. (Roy-Byrne & Cowley, 1990).  
BZDs may impair memory in two distinct ways: by causing acute amnesia (anterograde  
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amnesia) for a brief period of time following high dose parenteral administration and by 
impairment of recall that occurs during chronic BZD administration.  
Memory impairment also depends upon the dose and route of administration as a higher 
dose and intravenous administration may cause increased impairment. The differences in 
BZD users is also a factor in affecting memory since elderly patients and those with a 
history of sedative hypnotic drug use are more likely to report impairments. Alcohol can 
potentiate the actions of BZDs through direct effect on the chloride ion channels 
associated with the BZD receptor. At higher doses, alcohol and BZD use fail to produce 
any effect on account of maximum stimulation of chloride channels but at low doses they 
mainly have an additive effect (Roy-Byrne & Cowley, 1991).  
 BZDs may impair psychomotor functioning and consequently lead to impaired 
automobile driving when taken in acute as well as high doses. However, automobile 
driving is neither predictably nor consistently impaired by repeated therapeutic doses of 
BZDs and its also likely that therapeutic doses alone do not play a large role in accidents. 
Alcohol and advanced age increase the psychomotor toxicity of BZDs when taken on an 
acute or long-term basis (APA, 1990).  
The short half-life of BZDs in chronic use is found to increase the risk of cognitive 
impairment because notwithstanding the development of tolerance to psychomotor  
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impairment, cognitive impairment is observed subsequently after the use of these drugs 
(Roy-Byrne & Cowley, 1990). 
 2.8.3  Falls/Hip fractures in seniors 
The diminished capacity of the Phase I process in the elderly leads to accumulation of 
BZDs in the body. Accumulation of BZDs in the body may expose the patient to serious 
adverse effects.  In the community dwelling elders, the odds ratio for BZD associated 
falls is 1.48 (Leipzig, Cumming, & Tinetti, 1999). The number of medications taken by 
the elderly is directly proportional to the risk of falls (Cumming, 1998). Also, 
psychotropic medications have a strong causal relationship with falls in the elderly 
(Cumming, 1998). Epidemiological evidence shows that while approximately 10% of hip 
fractures could be due to BZDs, the use of BZDs significantly increases the risk of hip 
fracture by at least 50% in the elderly. In addition, the health care system and patients 
bear the high burden of mortality and morbidity caused by falls. Hence, it would be 
prudent to prescribe cautiously to older patients with their prescriptions meriting 
continuous supervision (Cumming & Le Couteur, 2003).  
2.9  Substance abuse 
BZD abuse can be defined by identifying two patterns: deliberate abuse to achieve 
euphoric effects and unintended misuse by patients who use the prescribed BZDs for  
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long-term inappropriately or at a higher dose than required (O’Brien, 2005).  
Deliberate abuse of BZDs usually starts with the misuse of prescriptions (which are either 
obtained from licensed medical practitioners or forged or bought) and ‘is usually a 
recreational and thrill seeking behavior’. Recreational abuse of BZDs alone is uncommon 
and is usually part of polydrug abuse (especially to augment methadone) in drug abuse 
and alcohol abuse populations. People who use BZDs for euphoric effects also use them 
for treating the withdrawal symptoms/adverse effects of alcohol or substance abuse 
(O’Brien, 2005).  
 The prescription of BZDs in persons with a history of substance drug abuse should be 
ideally avoided. But if deemed necessary, the use of BZDs in any person with actual or 
hypothetical predisposition to chemical dependence should be accompanied by constant 
and close monitoring for any signs of abuse or dependence such as tolerance, which 
includes escalation of dose and insistence on concomitant use of alcohol (Roy-Byrne & 
Cowley, 1990).  
2.10  Guidelines for prescribing BZDs 
As this study is part of a larger study which includes American physicians, the 
recommendations outlined in this section include those made by the WHO (1996), the 
Ministry of National Health and Welfare, Canada (Cooperstock & Hill, 1982), and the  
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American Psychiatric Association (APA, 1990).  
The prescription of BZDs is a complex process where a variety of factors should be taken 
into consideration before initiation of the prescription so that the patient can obtain 
maximum benefit from the therapy while experiencing no (ideally) or minimal harm.  
The guidelines, in general, recommend the following:    
1. Before prescribing, the physician should evaluate the patient using screening 
instruments, clinical interviews, general medical evaluation, physical examination, and 
laboratory procedures (to rule out liver/kidney dysfunctions) (WHO, 1996; Cooperstock 
& Hill, 1982).     
2. The patients should be presented with alternate therapies for their clinical condition(s) 
(WHO, 1996). 
3. The choice of BZDs should be made on the basis of elimination half-life, rate of 
absorption, metabolism of drug, and the adverse events expected to be experienced by the 
patient after ingestion (APA, 1990; WHO, 1996).   
4. The lowest dose to achieve the desired outcome for the shortest duration necessary 
should be prescribed (APA, 1990).  
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5. Long-term treatment should be practiced when benefits outweighs the risk (WHO, 
1996; APA, 1990).  
6. Treatment should be regularly reviewed for long-term users (APA, 1990).  
7. As sensitivity to BZDs increase with age, the elderly should be prescribed these drugs 
carefully (APA, 1990; Cooperstock & Hill, 1982). Long-acting BZDs with active 
metabolites should usually be avoided in the elderly (e.g. diazepam, chlordiazepoxide, 
flurazepam, nitrazepam). When BZDs are prescribed in older people, short-acting BZDs 
are preferred (Cooperstock & Hill, 1982). 
8. BZDs should be avoided in pregnant and lactating women (Cooperstock & Hill, 1982). 
According to the Centre for Addiction and Mental Health (2009), the non-BZD hypnotic 
zopiclone may be used during breastfeeding and, for short-term use, during pregnancy. 
9. Children can be given a BZD for a brief period if deemed necessary for seizures and in 
anaesthetic procedures (WHO, 1996; Cooperstock & Hill, 1982).  
10. Before prescribing, the physician should ascertain any drug abuse tendencies in the 
patient (APA, 1990).  
11. The guidelines recommend that BZDs be prescribed for one to two weeks for short-
term anxiety as it decreases the chances of dependence and provides the physician with  
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the chance to monitor individual dose-response (Cooperstock & Hill, 1982). 
12. For transient insomnia caused by disruption of circadian rhythms (such as in 
overnight travel, rapid transit over time zones, alteration of shift work or temporary 
admission to hospital), a hypnotic drug with a short duration of action and few residual 
effects would be appropriate to use on one or two occasions (WHO, 1996). For short-
term insomnia resulting from temporary environmental stress, hypnotics may 
occasionally be indicated, but should be prescribed in low dosages for one or two weeks 
only, or intermittently. As with their recommendations for anxiety and, (severe) insomnia 
too, BZDs may be prescribed for one to two weeks (Cooperstock & Hill, 1982). 
13. The Canadian guidelines (Cooperstock & Hill, 1982) further recommend the use of 
BZDs in the treatment of some types of continuous seizures, and for a variety of 
neuromuscular disorders such as cerebral palsy and tetanus.  
14. BZDs are safe and effective drugs to use in alcohol withdrawal. However, the side 
effects of memory impairment, drowsiness, and lethargy as well as the potential for 
dependence means that they may interfere with other therapeutic approaches dealing with 
stress management, coping behavior or drinking behavior modification. Therefore, BZDs 
used for this purpose should be in reduced dosages over a relatively short period of time, 
usually for no more than two weeks (WHO, 1996; Cooperstock & Hill, 1982). 
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15. Anaesthesia: Diazepam can be used as an intravenous anaesthetic during minor 
surgery, and in a variety of diagnostic tests generally administered in hospitals 
(Cooperstock & Hill, 1982).    
2.11 Rationale behind the inclusion of variables in the questionnaire for the survey 
examining BZD prescribing patterns of physicians in Newfoundland and Labrador 
 
The survey questionnaire is an adapted version of the questionnaire developed by the 
Maine Benzodiazepine Group. The respondents were measured on individual and 
practice characteristics, (factors influencing) prescribing patterns, guidelines awareness 
and uptake, and self –medicating behaviour. The data collection on the aforementioned  
parameters was to help me compare the individual and practice characteristics of 
physicians with other parameters and discover any significant patterns in BZD 
prescribing by physicians in Newfoundland and Labrador. 
 
In the following sections, I will be discussing the relevance of each parameter (Q1-17) in 
the questionnaire in context of the Canadian health care landscape only.  I have accessed 
and critically appraised observational (quantitative and qualitative) and interventional 
studies published in peer reviewed journals only. The key words used to search databases 
(mentioned in section 2.1) for the aforementioned literature search were: the parameter  
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under study (for example: gender), region under study (Canada), and focus of survey : 
‘benzodiazepines’ , and ‘physicians’. Additionally, I used the following key words: 
‘mental’ or ‘psychiatric’ or ‘neurolog*’. I have also gathered information from data 
published on government and professional bodies’ websites.  
 
2.11.1 Gender of physicians 
Gender of Canadian physicians was identified as one of the contributors to differing 
medical practice patterns (Garfinkel et al., 2004; Weizblit, Noble, & Baerlocher, 2009). 
Though neither survey directly addressed BZD prescribing habits of prescribers, it 
focused on questions concerning the quality of care provided to patients with mental 
health ailments. Gender-based variation in patients seen by clinicians and the different 
prescribing patterns of the clinicians may have implication(s) on the treatment outcomes 
among Canadians with mental health issues; for example: Garfinkel et al. (2004) reported 
that, among psychiatrists, women see more patients with anxiety disorders than men and 
men prescribe more pharmacotherapy to patients than women.  Furthermore, in 1990, a 
prescription database study revealed that male physicians (average of 65.2 BZD 
prescriptions) prescribed more BZDs to elderly patients (aged 65 years and older) than 
their female counterparts (average of 32.3 BZD prescriptions) (Thomson & Smith, 1995).   
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With more women entering the physician workforce in Canada, especially in the field of 
general/family practice (Canadian Institute for Health Information (CIHI), 2012), it 
becomes pertinent to explore the differences or similarities in BZD prescribing patterns 
of male and female physicians (Q1) in Newfoundland and Labrador. 
 
2.11.2 Practice setting of physicians 
A survey reported that general practitioners cited multidisciplinary settings as a facilitator 
to management of mental health concerns (Fleury, Farand, Aubé, & Imboua, 2012). 
Similarly, in a qualitative study, general practitioners reported multidisciplinary settings 
to be an enabling factor and lack of group practice settings to be a barrier to management 
of mental health disorders (Fleury, Imboua, Aubé, Farand, & Lambert, 2012). Evolving 
general practice is leading to almost half (40%) of physicians’ time being spent on adults 
with mental health issues (Collins, Wolfe, Fisman, DePace, & Steele, 2006). Depression, 
anxiety, and insomnia amongst others are considered mental health issues. Use of BZDs 
in such conditions is prevalent among Canadian patients (Bartlett, Abrahamowicz, Grad, 
Sylvestre, & Tamblyn, 2009; Cunningham et al., 2010; Hogan, Maxwell, Fung, & Ebly, 
2003). This prevalence brings forth the relevance of studying the effect of practice 
settings (Q6 and Q7) of the prescribers on their BZD prescribing habits. 
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2.11.3 Experience of physicians  
Prescriber characteristics such as year of graduation (Q3), which reflects the standards of 
basic training received, and years of practice (Q4), which reflects the experience in  
patient interaction and prescribing of medications, are parameters which contribute 
towards the selection of treatment modality(ies) for disease management (Sketris, 
Langille Ingram, & Lummis, 2007). A 1994 published study found that there was no 
significant association between prescribing for elderly patients with physician 
characteristics such as length of practice (in years), age, and practice size (Davidson, 
Molloy, Somers, & Bedard, 1994). However, a recent study (Eguale et al., 2012) reported 
differing prescribing patterns with respect to graduation year of physicians: medical 
graduates of recent years (1980-1989 and 1990-2004) (odds ratio: 1.08 and 1.08 
respectively) in comparison to earlier years (1960-1979) were significantly more likely to 
prescribe off-label medications. The same study found that more than 90% of the off-
label prescriptions for clonazepam and oxazepam have been associated with its off-label 
use without any supporting scientific evidence.  Furthermore, 43.6% of the patients with 
insomnia and 46.5% of the patients with generalized anxiety disorders were analyzed to 
be prescribed off-label drugs including BZDs. Though this study focused upon off-label 
use of medications, the statistically significant associations between insomnia and 
clonazepam along with generalized anxiety disorders and oxazepam merits the inclusion  
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of parameters which study the effect of length of practice (and time since completion of 
medical studies) of the prescribers. 
 
2.11.4 Cohort (specialty) of physicians, types of BZDs prescribed, and indications for 
the use of BZDs 
In Canada, more than half of the physician workforce is accounted for by general 
practitioners (CIHI, 2012). From 1997 to 2006, family physicians were increasingly 
prescribing more medications (including psychotropic medications)  to older Canadians 
(Bajcar et al., 2010). More than half of the general practitioners in Quebec, Canada were 
found to be either monitoring the pharmacotherapy (61.1%) or providing ‘support 
therapy’ to patients (59.3%) with common mental health issues (Fleury, Farand, et al., 
2012). BZDs are mainly labeled for mental health indications and as anti-convulsant 
medication (Canadian Pharmacists Association or CPA, 2008). In this survey (Q8), 
examining BZD prescribing trends with respect to prescribers’ specialties such as 
neurology, psychiatry, and family medicine (general practice) will help me compare the 
similarities and differences in the prescribing patterns of each cohort of physicians. It is 
pertinent to note that this survey was mailed to all physicians registered with Professional 
Development and Conferencing Services (PDCS), Faculty of Medicine, Memorial 
University of Newfoundland and Labrador, to examine the prescribing trends of BZDs  
39 
 
within all cohorts of physicians. 
The list of BZDs (Q10) presented in this survey matches the approved list of drugs in 
Canada (Table 2.1) and includes BZDs (estazolam and quazepam) available in the United 
States. It has been noted that direct to consumer advertising in the United States has 
significant impact on the Canadian stakeholders’ (patients) perceptions of drug therapy 
(Mintzes et al., 2003 ). Furthermore, different BZDs have varying levels of risks for fall 
related injuries in the elderly; for example, lorazepam was not only the highest prescribed  
BZD among new elderly users (n= 10,197) but also had the largest cohort of fall related 
injuries (n= 841) when compared to other BZDs (Sylvestre, Abrahamowicz, Capek, & 
Tamblyn, 2012). Given this context, understanding the extent of prescribing for each 
BZD (Q10) in Newfoundland and Labrador will help me understand the prevalence of 
available BZDs from the prescriber’s point of view. The pharmacological actions of BZD 
(anxiolytic, hypnotic, anticonvulsant, amnestic, and myorelaxant) are generally in 
congruence with its approved indications (see Table 2.1). Indications (Q11) listed in the 
questionnaire reflect the approved indications of BZDs (see Table 2.1 ) and indications 
listed in the review article by Longo & Johnson, 2000. Also, off-label use of BZDs has 
been noted for depression, grief reaction, nausea (anti-vertigo), and severe agitation 
associated with mania (bipolar disorder) (Eguale et al., 2012; Rechinsky, 2011).  
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2.11.4.a  Indications and clinical uses of BZDs: Though BZDs are mainly associated with 
symptom management of insomnia and anxiety, they are also used in other clinical 
conditions. As mentioned earlier on page 1, BZDs have five pharmacological actions. 
They are therefore clinically used in the treatment of conditions which are associated 
with these aforementioned pharmacological actions. Following are the clinical uses of 
BZDs (Longo & Johnson, 2000):  
1. Anxiety disorders  
a. Acute anxiety  
b. Generalized anxiety disorder  
c. Panic disorder  
d. Phobias (social, simple)  
e. Post-traumatic stress disorder  
f. Obsessive-compulsive disorder  
g. Anxiety associated with medical illness: cardiovascular, gastrointestinal, 
somatoform disorder    
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2. Insomnia  
3. Convulsive disorders  
a. Acute status epilepticus  
b. Neonatal seizures or febrile convulsions  
c. Preeclampsia  
d. Tetanus  
e. Adjunct to other anticonvulsants  
4. Amnestic (before surgery or procedure)  
5. Spastic disorders and other types of acute muscle spasm: cerebral palsy, multiple 
sclerosis and paraplegia secondary to spinal trauma  
a. Involuntary movement disorders  
b. Restless leg syndrome  
c. Akathisia associated with neuroleptic use  
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d. Choreiform disorders  
e. Myoclonus  
6. Detoxification from alcohol and other substances  
7. Other adjunctive uses: Surgery, Dentistry    
8. Diagnostic studies, such as computed tomography, magnetic resonance imaging, and 
endoscopy    
9. Cardioversion and Chemotherapy  
Table 2.1 (see below) is adapted from eCPS, which outlines the labeled indications for 
each type of BZD which is available in Canada (CPA, 2008). 
43 
 
Table 2.1 Labeled indications for BZDs available in Canada.  
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Alprazolam  Yes      
Bromazepam  Yes      
Chlordiazepoxide  Yes      
Clobazam     Yes   
Clonazepam     Yes   
Clorazepate  Yes   Yes  Yes 
Diazepam  Yes  Yes Yes Yes Yes 
Flurazepam   Yes     
Lorazepam  Yes  Yes Yes   
Midazolam    Yes    
Nitrazepam   Yes Yes   
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Oxazepam  Yes     Yes 
Temazepam   Yes     
Triazolam   Yes     
 
Note: a: Used in adults and children. 
The present survey also includes zopiclone, zolpidem and zaleplon (also known as “Z” 
drugs or BZD-like / non-BZD drugs). They are primarily used to manage insomnia. 
Zopiclone and zolpidem along with BZDs are approved as sleep aid medications (Health 
Canada, 2009). 
 
2.11.5 Enquiry into reason(s) to continue prescribing BZDs beyond 90 days 
A 5-year database (1990-1994) study examined the BZD prescription patterns in new 
users among the elderly Canadian population aged 65 years and older (Bartlett et al., 
2004). Though this study excluded ‘geographically isolated’ patient groups in Quebec 
and hospitalized patients and did not examine actual BZD consumption, it did capture 
data pertaining to 89% of the elderly population. The following results were reported:  
45 
 
45% of the patients in this study had a single period of continuous BZD use for more than 
30 days. The mean number of distinct periods for uninterrupted BZD use was 3.2 
(standard deviation 3.3).  As the majority of patients had greater than 1 period of 
uninterrupted BZD use, assessing the reasons for prescribing BZDs beyond 90 days 
(average duration of single period of uninterrupted BZD use (minimum days) X average 
number of periods of continuous use: 30 X 3: 90 days) would elucidate the prescriber’s 
viewpoint to continuously prescribe BZDs (Q12) for more than the recommended period 
of time (Cooperstock & Hill, 1982). Furthermore, long-term BZD use or inappropriate 
prescriptions have been defined as BZD use beyond 90 days (Preville et al., 2012).   
2.11.6 Prescribing more than one BZD to the same patient 
As discussed in section 2.4, inappropriate prescriptions of two or more BZDs were found 
among Newfoundland and Labrador seniors (NLCAHR, 2003). Question 13 (a and b) of 
the survey is to elicit the prescriber’s point of view regarding the use of more than one 
BZD in the same patient and the reasons behind these actions. 
 
2.11.7 Factors influencing BZD prescribing habits of physicians in Newfoundland and 
Labrador 
Health Council Canada’s background paper ‘Optimal Prescribing and Medication Use in  
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Canada’ acknowledges suboptimal prescribing in Canada and discusses interventions to 
improve it. As per the paper, the decision-making process for a prescription is influenced 
by variables associated with: 1. prescriber demographics and attitudes, 2. practice setting, 
3. medication, 4. patient, and 5. external factors such as detailing by pharmaceutical 
representatives, regulations by government, etc. (Sketris et al., 2007). 
2.11.7.a  Medication related factors: The influence of drug interactions needs to be taken 
into account prior to prescribing BZDs as there was a three fold increase in prescriptions 
among the elderly (aged 65 years and over) from 1997 to 2006 (Bajcar et al.,  
2010). Among community dwelling elderly populations, about 23% of BZD users were 
exposed to a risk of drug- drug interactions due to simultaneous prescriptions for  BZDs 
and other drugs (Preville et al., 2012).  Medication related factors (Q14) such as side 
effects, indication, and effectiveness of drug are parameters influencing the decision-
making process of clinicians in prescribing a drug. For example, while temazepam was 
effective in alleviating insomnia in a 2-week randomized clinical trial in subjects aged 70 
years and older, its relative effectiveness (with respect to diphenhydramine) in the 
management of insomnia needs to be weighed against the risk of falls when considering 
its prescription (Glass, Sproule, Herrmann, & Busto, 2008). This adverse effect of BZDs 
was validated via database study by Sylvestre et al., 2012, who concluded that current 
and past exposure to BZDs increases the risk of fall-related injuries in seniors. The 
importance of the risk of BZD abuse is elucidated in section 2.9. 
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2.11.7.b  Peer group: As part of a quality improvement initiative, the implementation of a 
practice support program (peer to peer training) for general practitioners and their staff in 
British Columbia was evaluated (via survey) for its perceived impact on clinical practice 
and patients. In this survey, 41% and 20.8% of general practitioners reported a decrease 
and increase respectively in prescribing medications after attending the Adult Mental 
Health Module. While this is an equivocal response to peer facilitated intervention, the 
long-term impact assessment for the same program revealed that general practitioners had 
sustained their confidence in prescribing medications for mental health conditions 
(MacCarthy et al., 2012). Though selection bias and difficulty in verifying the actual 
sample size are limiting factors for this study, consultation with peers can be concluded 
as one of the factors affecting quality of care by clinicians (Q14). 
 
2.11.7.c  Insurance coverage, cost of medication, and drug availability: Provincial 
formulary listing of any drug is the result of clinical and pharmacoeconomic evaluation 
of the drug by the Canadian Drug Expert Committee, which is an advisory body to the 
Canadian Agency for Drug and Technologies in Health (a government agency providing 
evidence based recommendations on health care to all decision makers) (Canadian 
Agency for Drugs and Technologies in Health, 2013). With respect to seniors in 
Newfoundland and Labrador, the cost of selective medications is reimbursed through the 
65Plus plan (Government of Newfoundland and Labrador, 2013 ).  Canadian physicians  
48 
 
refer to the formulary as an important tool in their decision making process to prescribe 
medications to seniors aged 65 years and older but mention that inequity in access to 
medications and time lost in filling paperwork for the reimbursement process are 
constraints to using the formulary effectively (Suggs et al., 2009). The impact of factors 
such as insurance and cost of medications  (Q14) can lead to a better understanding of 
barriers and facilitators in optimal BZD prescribing among Newfoundland and Labrador 
physicians.  
 
2.11.7.d  Pharmaceutical industry and physicians’ relations : The Canadian public does 
not have negative views on industry-physician interactions wherein information on the 
medication is shared (Holbrook et al., 2013). Similar perceptions are held by Canadian 
residents who actively sought drug-related data from the pharmaceutical industry 
(McCormick, Tomlinson, Brill-Edwards, & Detsky, 2001).  Given that the majority of 
such interactions (64%) result in a prescription (Mintzes et al., 2013), it is pertinent to 
understand the impact of the pharmaceutical industry on clinicians’ prescribing patterns 
(Q14).  
 
2.11.7.e  Availability and affordability of counselling: It was noted that family physicians 
in Ontario have a decreased belief in psychotherapy as an effective treatment modality 
for older patients with mental health issues  (Mackenzie, Gekoski, & Knox, 1999). A  
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shift in that perspective was observed; a recent study showed that general practitioners 
noted collaboration with a psychiatrist or access to specialized mental health services as 
facilitators to providing quality of care to mental health patients (Fleury, Imboua, et al., 
2012). Non-pharmacological therapy such as cognitive behavioural therapy is postulated 
to be cost effective in the international arena, though this finding is yet to be ascertained 
in a Canadian context (Myhr & Payne, 2006). Examining the influence of such non 
pharmacological variables (Q14 & Q16) on BZD prescribing patterns of physicians in 
Newfoundland and Labrador is important as BZDs are prescribed for indications which 
may be managed by non-pharmacological therapy (Jensen & Regier, 2010). 
 
2.11.7.f  Patients’ requests: A pan-Canadian survey among the English speaking 
members of the College of Family Physicians of Canada noted an increase (82.7%) (95% 
CI 75.3% to 88.3%) in the prescribing of antibiotics for lower respiratory tract infections 
by family physicians when faced with pressure from patients compared with 46.5% (95% 
CI 39.3% to 53.8%) when no pressure was felt (McIsaac & To, 2004).  Though this study 
is on a different class of drugs and may incur responder’s bias due its nature of 
methodology, it does report a statistically significant relationship between prescribing 
and the patient’s demand for a prescription. Studying the effect of this parameter (Q14) 
on BZD prescribers (physicians) can bring forth the contribution of patients in the clinical 
decision-making process. 
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2.11.7.g  Clinical practice guidelines: For adult (18 to 64 years) patients, receiving 
pharmacological treatment in accordance with mental health guidelines demonstrated a  
reduced need for hospitalization although it did increase the number of clinical meetings 
with the prescriber (Sewitch, Blais, Rahme, Bexton, & Galarneau, 2007). A 2006 
database study (Cunningham et al., 2010)  concluded that 3.5% of residents (all age 
groups) of British Columbia were using  BZDs for more than 100 days and the elderly 
population accounted for nearly half of the long term users. This study reported a 
decrease of BZD use in patients over 70 years and an increase of BZD use among the 
middle aged patients from 1996 to 2006. Furthermore, it surmised that disseminated 
literature (including guidelines) had little effect on the patterns of BZD use. One of the 
limitations of this dataset study is that it assumed prescriber awareness of BZD related 
literature and  further assumed the prescriber’s agreement with the findings and 
recommendations in such literature. Another approach to study the effects of guidelines is 
in conjunction with other tools (such as continuing medical education or CME) which 
may help improve the uptake of recommendations/policy statements. One such study 
(Rahme et al., 2005) reported that CME along with the provision of guidelines (in 
comparison with no intervention) can optimize the prescribing patterns of general 
practitioners for elderly patients with osteoarthritis.  The findings of this study are 
relevant to my thesis because it focused on prescribers’ prescribing to a population 
similar to one served by the sample in my survey. Though guidelines have not shown to  
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reduce the incidence of BZD prescriptions as per the Health Transition Fund Report 
(Kennedy & Goyer, 2002), Canadian family physicians have expressed positive views on 
evidence based medicine (guidelines) (Hayward et al., 1997). The questions pertaining to 
the degree of adoption of guidelines (Q14), source and disagreements with the guidelines 
(Q15) and guidelines as a useful tool to optimize prescribing habits (Q16) can be helpful 
in the development of BZD CPG. 
 
2.11.8 Continuing medical education by an expert  
Self-reported CME needs were assessed among newly licensed Canadian family 
physicians in 2001. Rural family physicians were significantly more likely to cite the 
need for CME for mental health concerns than their urban counterparts (47.4% v. 30.8%; 
p=0.043) (Curran et al., 2007). As the survey population in the study by Curran et al., 
(2007) included a lower proportion of members practicing in the field of geriatrics and 
psychotherapy than other certified members of the College of Family Physicians, the 
aforementioned values may be an underestimation of the actual needs of the specific 
cohort of family physicians. CME can take different forms and approaches. One effective 
approach is an in-person lecture by a peer physician who is considered a subject matter 
expert across multiple points of care (Wright et al., 2008). This clinical trial by Wright et 
al. (2008) was conducted among surgeons and pathobiologists, which limits its resonance 
to certain a cohort of physicians. Its findings regarding the effectiveness of CME  
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by experts was similar to a study focusing on the effects of online education provided by 
an expert on opioid and BZD prescribing skills to family physicians (Midmer, Kahan, & 
Marlow, 2006). The respondents in the study by Midmer et al. (2006) reported a 
significant increase in the counseling of patients on sleep hygiene after an email based 
discussion of cases with an addictions physician (expert) (before-after difference = 0.24; 
p= 0.03). Though the physicians reported an increase in counseling for sleep hygiene, the 
online discussion with the expert neither resulted in improved management of patients 
with BZD dependence nor was it successful in improving their belief in better outcomes 
for patients with BZD dependence, anxiety disorders or insomnia. In the present study, 
the question (Q16) on CME by an expert is pertinent to understanding the current 
educational needs of Newfoundland and Labrador physicians, especially for rural 
clinicians (Q5). 
2.11.9 Personal use of BZDs by physicians   
Raza, Ilnyckyj, & Bernstein (2006) proposed that the age and practice region of Canadian 
specialists were significant correlates for their compliance with colorectal screening 
guidelines; younger specialists (50 to 65 years) were more likely to get screened for 
colorectal cancer than specialists aged 65 and older, and specialists in the Maritime 
provinces were less likely to get themselves screened than their counterparts in the rest of  
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Canada. This survey focused on personal choices of prescribers on undergoing preventive 
health measures (rather than therapeutic medication as is the case in the present survey). 
While the extrapolation of its conclusions to my present survey sample or central theme 
is limited as it excluded general practitioners, the survey does shed some light on the 
personal choices and behaviours of prescribers (specialists). One of the findings in the 
survey by Raza et al. (2006) indicated disagreement with current knowledge on disease 
management to be one of reasons cited by specialists who chose not to undergo screening 
for colorectal cancer. Since personal health choice(s) of physicians may play a role in the 
work place functioning of physicians and quality of care provided to patients, the 
question pertaining to personal use (Q17) is presented to explore the possibility (and/or 
extent) of self-medication with the drug (BZDs) among the respondents. 
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Chapter 3: Methodology:  
3.1 Study type/design  
A cross-sectional postal survey was conducted among physicians throughout the province 
of Newfoundland and Labrador. The survey consisted of a cover letter (1 page) 
(Appendix A) and a self-administered questionnaire (2 pages) (Appendix B), which was 
mailed to the study population with a request to return the completed questionnaire in the 
pre-addressed business reply envelope within a month. The design of this survey protocol 
included two contacts with the study population in order to ensure better response rate. 
The first contact was to approach the physicians (respondents) to participate in the survey 
as well as screen out those who were no longer practising in Newfoundland and 
Labrador. The numeric code on the return envelope of the first mail out was only to know 
the identity of the non-respondents in order to send the replacement questionnaire to 
them. The second contact via the replacement questionnaire was made with non-
respondents only. Similar to the first contact, the second contact cover letter (Appendix 
C) requested the respondents to return the completed questionnaire in the pre-addressed 
business reply envelope. The survey was anonymous and completely voluntary. The staff 
at PDCS, Faculty of Medicine, Memorial University separated the completed 
questionnaires from their envelopes so that none of the study team members could  
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identify the respondents with their answers. While the cover letters were individually 
signed to invoke a feeling of personalization, they were addressed as “Dear Doctor” to 
maintain anonymity in case they were returned with the completed questionnaires. The 
list of physicians was obtained from the offices of PDCS.  The physicians were not given 
any compensation for their participation. The study documents were mailed via regular 
Canada Post. 
Relevance of survey design: The study was designed as a postal survey to maintain 
anonymity, to give the respondents a choice to complete the questionnaire at his/her 
convenience and to conduct the study with limited finances.    
Limitation of the design: Online resources were not explored to conduct the survey.    
3.2 Target population 
 PDCS is ‘an academic and service unit of Faculty of Medicine (MUN)’ which provides a 
range of services including research related surveys in addition to its mission to support 
the fulfillment of the Faculty of Medicine’s continuing professional development 
mandate through educational research and development. Therefore, its database is 
constantly updated and can be viewed as a reflection of the physician population in 
Newfoundland and Labrador. All physicians (N = 984) registered with PDCS were 
approached to take part in this survey. The study population included all specialities of  
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physicians. This was due to the fact that BZDs have a wide range of pharmacological 
actions and, can be prescribed by any physician. 
3.3 Survey instrument development 
The questionnaire was initially conceived and developed by the Maine Benzodiazepine 
Group in 2005 to conduct a survey among the physicians in Maine. For the present study, 
the questionnaire (Appendix B) was revised for the following reasons:  
i. to better reflect the Newfoundland and Labrador drug utilization scenario.  
For example: A recent study conducted by SOP-MUN, NLCHI, DCH-MUN, DoHCS and 
NPA showed that elderly patients in Newfoundland and Labrador are concurrently or 
subsequently prescribed more than one BZD (NLCAHR, 2003). The guideline by WHO 
(1996) explicitly states that only one BZD should be prescribed per patient hence 
question 13 was incorporated to enquire about concurrent prescribing of more than one 
BZD to the same patient and the reason(s) for this action.  
ii. to present an exhaustive (wherever possible) list of choices to the respondents.  
For example:  
a. the list of medications in question 10 which asked the respondents about the currently  
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prescribed medications included all the BZDs available in Canada as well as the United 
States along with the “Z” drugs zolpidem, zaleplon and zopiclone. b. all the basic 
pharmacological actions of BZDs along with the top five answers (received in the Maine 
survey) and the original choices were listed in question 11 which enquired about the 
reasons to prescribe BZDs.  
Furthermore, the modifications to the questionnaire were based upon the findings from 
the literature (Chapter 2, section 2.11) review and recommendations by 4 reviewers. 
Survey instrument: The survey instrument consisted of a cover letter and copy of the 
questionnaire. The cover letter outlined the study objective, study design, and 
administrative details such as the deadline, etc. It also pointed out the confidentiality, 
anonymity and voluntary nature of the survey. The questionnaire consisted of two 
sections. Section 1 had questions pertaining to the demographic information of the 
respondents: age, gender, speciality, years of medical practice, year of completion of 
medical education, practice population, practice type (multidisciplinary/group/solo), 
practice setting (hospital/office etc.), and finally, whether the respondent currently 
prescribes BZDs.  
Section 2 collected data regarding the prescribing patterns of physicians.  
The section starts with questions on the types of BZDs ( in addition to the “Z” drugs and  
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Carisaprodol) prescribed and is followed by questions on the reasons for prescribing 
BZDs as well as reasons for prescribing these drugs beyond 90 days. Question 13 
enquires about the concurrent prescribing of more than one BZD to the same patient. 
Question 14 deals with 14 factors affecting the prescribing of the medication. The rate of 
agreement on the influence of each factor on prescribing medications was marked on a 7-
point Likert scale, in which “1” indicated total disagreement and “7” indicated total 
agreement. The next questions were to understand the opinion(s) regarding the guidelines 
used to prescribe BZDs and the most suitable method for disseminating information 
which can help improve the prescribing of medications by the physicians. The survey 
ended with the question regarding personal usage of BZDs by the respondents beyond 
30/60/90 days. Each question was a multiple choice with the option of recording one’s 
own response under the ‘others’ category to gather a response(s) not included in the list.  
3.4 Validity and reliability of the cover letters and questionnaire 
This questionnaire was developed to study the prescribing patterns of this particular study 
sample only and hence it was not tested for reliability. The external validity of the cover 
letters (Appendix A and Appendix C) and questionnaire (Appendix B) was judged by 4 
reviewers: two physicians, one epidemiologist, and one pharmacist. Recommendations 
made by all 4 reviewers were incorporated into the survey instrument. 
3.5 Ethical considerations 
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This study was approved by the Human Investigation Committee (HIC) at Memorial 
University of Newfoundland; it was conducted as per the methodology stated in the 
ethics submission application and as per the policies outlined by HIC. The respondent’s 
consent to participate was implied by the return of the completed questionnaire. The 
study design ensured anonymity of the respondents.  
3.6 Steps for data analysis 
The data was tabulated in MS ACCESS, graphs were prepared in MS EXCEL and 
statistical analysis was performed using SPSS version 16. The data was double checked 
to ensure zero percent error and accurate representation of the results. The data analysis 
included a descriptive analysis (measures of central tendency, standard deviation, 
frequencies, percentages, and range). Additionally, the chi square analysis and the 
Fisher’s exact test were employed between the independent (Section 1) variables and the 
dependent (Section 2) variables (p was set at 0.05). The qualitative analysis was 
performed on the responses recorded under ‘other’ by grouping similar responses 
together.  
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Chapter 4: Results  
This chapter deals with the results taken from the data analysis. The details of data 
analysis are mentioned in methodology section. The descriptive analysis is presented in 
two sections as the questionnaire also is divided into two sections. The results of the 
inferential statistics are presented along with the relevant effect size (phi or Cramer’s v). 
The effect size is calculated to measure the strength of association between two variables. 
The effect sizes mentioned in this study are interpreted according to Cohen’s standards 
(Valentine & Cooper, 2003).  
Sample size results:  
297 prescribers (out of 984 approached) from Newfoundland and Labrador responded to 
this survey. 16 questionnaires were sent back with the “return to sender” mark on them 
and following reasons were cited: recipient moved away (15) or deceased (1). Response 
rate for the survey was therefore 30.68%. The average response rate for mailed surveys 
among health care professionals was concluded to be 57.5%; the low response rate to this 
survey may be due to the use of business reply return envelopes1, lack of pre-notification 
for this survey, physicians’ policy to not participate in surveys, limitations in the PDCS 
database, and inclusion of question pertaining to BZD personal use by prescribers 
                                                 
1 Use of (first class) stamped return envelope increased the response rates to postal surveys amongst 
physicians and general population as well. 
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because it may have been deemed as a ‘sensitive’2 question by respondents (Cook, 
Dickinson, & Eccles, 2009; Edwards et al., 2009; VanGeest, Johnson, & Welch, 2007; 
Wiebe, Kaczorowski, & Mackay, 2012). 
The questionnaire collected data with respect to the demographic (section 1) and 
prescribing patterns and the factors affecting them (section 2).  
                                                 
2 Amongst all sections of population, inclusion of ‘sensitive’ questions reduced the rate of response to 
postal surveys. 
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Section 1  
Analyses of all respondents to the survey (Sample size N = 297)  
The majority, 183 (64%) of the respondents were male. Furthermore the majority of 
respondents were : between the age of 45 to 54 years [99 (37.9%)], had practiced for 20 
to 29 years [89 (31.6%)], completed their studies between 1975 to 1984, [94 (33.5%)], 
practiced in population of 100,000 or more [152  (53.9%)]. Most of respondents practiced 
in an office setting [123 (48%)], in a group [143 (56.1%)], were general practitioners 
[129 (49.4%)] and finally, did prescribe BZD to their patients [233 (78.5%)]. 
Analyses of the respondents who prescribe BZDs (Sample size N = 233)  
 Table 4.1 and Figures 4.1 through 4.5 display the results of the descriptive analyses of 
the demographic information of the respondents who prescribe BZDs. As seen in the data 
of the overall respondents, the majority of the respondents are: male, in the age group of 
45 to 54 years, general practitioners, practiced in a group setting, and have had 20 to 29 
years of practice. The respondents are concentrated in urban areas. Note that there is no 
significant difference between BZD prescribers and non-prescribers among the 
respondents in this survey. 
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Figure 4.1 below displays gender characteristics of respondents who prescribe BZDs. As 
shown clearly below, more number of male respondents prescribe BZDs in their practice. 
 
Figure 4.1 Gender  of respondents prescribing BZDs (Actual N = 229; Missing  = 4) 
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With respect to age of the respondents who prescribe BZDs (Figure 4.2), majority of 
respondents ( 36.5%) belong in 45 to 54 years category, followed by 35 to 44 years old 
respondents ( 26.0%), then 55 to 64 years (19.2%) , 25 to 34 years (14.4%), and finally, 
65 to 74 years old respondents (3.8%).  
 
Figure 4.2 Age of the respondents prescribing BZDs ( Actual N = 208; Missing = 25) 
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Figure 4.3 below shows that the majority of respondents (32.7%) have practiced for 20 to 
29 years and least number of respondents (2.7%) have 40 to 49 years of experience. 
24.3%, 23.0%, and 17.3% respondents have practiced for 0 to 9 years, 10 to 19 years, and 
30 to 39 years respectively.  
 
 
Figure 4.3 Years of practice of respondents prescribing BZDs (Actual N = 226; Missing = 
7) 
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Respondents mainly practiced (Figure 4.4) in areas with population density of 100,000 or 
more (48.0%), followed by :10,000 to 24,999 (17.2%), 5000 to 9,999 (13.7%), 2000 to 
4,999 (8.8%), 25,000 to 49,999 (5.7%), less than 2000 people (3.5%) and finally, in area 
with population between 50,000 and 99,999 (3.1%). 
 
Figure 4.4 Population of community in which respondents prescribing BZDs practice 
(Actual N = 227;Missing = 6) 
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As seen below in Figure 4.5, respondents who prescribe BZDs mainly practiced in group 
setting (57.4%) and least number of respondents (1.5%) have marked both, alone as well 
as multidisciplinary setting as their practice setting. 
 
Figure 4.5 Practice setting of respondents prescribing BZDs (Actual N = 202; Missing 
=31) 
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Table 4.1  The descriptive statistics of the respondents who prescribe BZDs (Sample size 
N = 233)  
Variable  N = 233  Actual N 
(100%)  
Missing  
  Count  Percent  
Year of completion of 
medical studies  
   226 7 
1975 to 1984  73 32.3 
   
1985 to 1994  66 29.2 
1995 to 2004  52 23
1965 to 1974  26 11.5 
2005 to 2007  6 2.7 
1955 to 1964  3 1.3   
Practice Setting     202 31 
Office practice  108 53.5 
   
Hospital based  77 38.1 
Hospital based and Office 
practice  
10 5
Public clinic  6 3 
Nursing Home  1 0.5 
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Variable  N = 233  Actual N 
(100%)  
Missing  
  Count  Percent  
Specialty     203 30 
General Practitioners  129 63.5 
   
Others  74 36.5 
   
The following is the detailed breakdown of all the respondents by “specialty”:  
63.5%  General practitioners, 3.5% adult psychiatrists,  1.4%  child psychiatrists, 0.5% 
forensic psychiatrists,  2.0%  neurologists,  4.4%  surgeons. 24.6% were classified as 
‘‘other’’ and belonged to approximately 30 different specialties including surgeon, 
geriatrician, internist, urologist, paediatrician, occupational medicine, and resident.  
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Section 2  
The second section on the questionnaire had detailed questions regarding the prescribing 
patterns of the respondents who answered “yes” to question 9 (in Section 1).   
1.Types of BZDs currently prescribed:  
The prescribers were first asked to mark the name(s) of medication(s) (drug molecule and 
brand name) they prescribe with respect to BZD types of drugs.  
Table 4.2 below shows a dominance of high potency BZDs. Over 90% of the respondents 
indicated to currently prescribe a short-acting BZD: lorazepam (high potency short- to 
intermediate-acting BZD). The second most prescribed drug was zopiclone which is a 
BZD type hypnotic, which was followed by clonazepam (high potency long-acting BZD), 
temazepam (low potency short- to intermediate-acting BZD) and diazepam (medium 
potency long-acting BZD) (in that order).  
 Table 4.2 The descriptive statistics of the types of BZDs which are currently prescribed 
by respondents 
Drug molecule (Brand name)  Response: Yes (Count) Response: Yes (Percent)  
1. Lorazepam (Ativan®)   216 93.9
2. Zopiclone (Imovane®)                159 69.1
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Drug molecule (Brand name)  Response: Yes (Count) Response: Yes (Percent)  
3. Clonazepam(Rivotril®)                144 62.6
4. Temazepam (Restoril®)               137 59.6
5. Diazepam (Valium®)                    123 53.5
6. Oxazepam (Apo-Oxazepam®)     108 47.0
7. Alprazolam ( Xanax®)                 91 39.6
8. Bromazepam (Lectopam®)          67 29.1
9. Midazolam ( Apo-Midazolam 
Injectable®)  
57 24.8
10. Triazolam ( Halcion®)                45 19.6
11. Chlordiazepoxide ( Apo-
Chlordiazepoxide®)            
43 18.7
12. Nitrazepam (Mogadon®)            21 9.1
13. Flurazepam (Dalmane®)            17 7.4
14. Clobazam  (Frisium®)                16 7.0
15. Zaleplon (Starnoc®)                   13 5.7
16. Clorazepate (Novo-
Clopate®)       
12 5.2
17. Estazolam (ProSom®)                2 0.9
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Drug molecule (Brand name)  Response: Yes (Count) Response: Yes (Percent)  
18. Zolpidem (Ambien®)  1 0.4
19. Carisoprodol (Soma®)                1 0.1
20. Quazepam(Doral®)                     0 0
21. Other(s) (please specify)  0 0
 
Note: 1. Sample Size N = 230 (3 missing responses). 2. Options were not mutually 
exclusive hence one prescriber could mark more than one BZDs.   
Significant results:   
As shown in Table 4.3 below, gender and years of medical practice played an important 
role in prescribing of triazolam. Psychiatrists tend to prescribe clonazepam more than 
general practitioners.  Older (48 to 71 years) physicians were more inclined to prescribe 
chlordiazepoxide, flurazepam, temazepam and clobazam than their younger (27 to 47 
years old) counterparts. Physicians practicing in a demographic population of less than 
25,000 were more inclined to prescribe nitrazepam, bromazepam and chlordiazepoxide 
than those practicing in an area with 25,000 or more people. Physicians who practice in 
group or multi-disciplinary unit were more likely to prescribe lorazepam than those who 
practice alone. Each of these results had a small effect size.  
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Table 4.3 The significant results from the chi-square analyses between demographic 
variables and the types of BZDs which are currently prescribed  
Type of BZDs 
prescribed by 
physician (N) 
 Demographic 
characteristic 
of physician 
(NN) 
% of NN 
= Yes’  
Chi-square / 
Fisher’s 
exact  
p  Effect size= 
small/moderate 
/large 
Triazolam (229) Male (146) 24 5.877 0.015 0.160 =small 
  Female (83) 10.8      
Clonazepam (140) General 
practitioner 
(129) 
69.8 0.023     
  Psychiatrist (11) 100      
Triazolam (226) Phys with 20 to 
50 years of 
medical 
practice( 119)  
24.4 0.036     
  Phys with 0 to 
19 years of 
medical practice 
(107)  
14      
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Type of BZDs 
prescribed by 
physician (N) 
 Demographic 
characteristic 
of physician 
(NN) 
% of NN 
= Yes’  
Chi-square / 
Fisher’s 
exact  
p  Effect size= 
small/moderate 
/large 
Clobazam (208) Older (48 to 71 
years) phys 
(103) 
11.7 4.502 0.034 0.147 =small 
  Younger (27 to 
47 years) phys 
(105) 
3.8      
Bromazepam 
(227) 
Phys practicing 
in area with 
more than 
25000 people 
(129) 
21.7      
  Phys practicing 
in area less than 
25000 people 
(98) 
38.8 7.869 0.005 0.186 =small 
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Type of BZDs 
prescribed by 
physician (N) 
Demographic 
characteristic of 
physician (NN) 
% of NN 
= Yes’  
Chi-square / 
Fisher’s 
exact  
p  Effect size= 
small/moderate 
/large 
Chlordiazepoxi
de 
(227 ) 
Phys practicing in 
area less than 
25000 people (98) 
27.6 8.323 0.004 0.191 =small 
  Phys practicing in 
area with more 
than 25000 people 
(129) 
12.4      
Nitrazepam 
(227) 
Phys practicing in 
area less than 
25000 people (98) 
13.3 4.259 0.039 0.137 =small 
  Phys  practicing in 
area with more 
than 25000 people 
(129) 
5.4      
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Type of BZDs 
prescribed by 
physician (N) 
 Demographic 
characteristic 
of physician 
(NN) 
% of NN 
= Yes’  
Chi-square / 
Fisher’s 
exact  
p  Effect size= 
small/moderate 
/large 
Flurazepam (208) Older (48 to 71 
years) phys 
(103) 
11.7 4.502 0.034 0.147 =small 
  Younger (27 to 
47 years) phys 
(105) 
3.8      
Temazepam (208) Older (48 to 71 
years) phys 
(103) 
69.9 10.647 0.001 0.226 =small 
  
  
Younger (27 to 
47 years) phys 
(105)  
47.6      
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Type of BZDs 
prescribed by 
physician (N) 
 Demographic 
characteristic 
of physician 
(NN) 
% of NN 
= Yes’  
Chi-square / 
Fisher’s 
exact  
p  Effect size= 
small/moderate 
/large 
Lorazepam (199) Phys who 
practice in 
group or multi-
disciplinary unit 
(167)  
95.8 0.027     
  Phys who 
practice alone 
(32) 
84.4      
   
Note: 1. The degree of freedom for all reported results in Table 4.3  is 1. 2. No effect size 
is calculated for results reporting Fisher’s exact test. 
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2. Reasons to prescribe BZDs: 
Prescribers were asked to indicate the reason for prescribing BZDs (Table 4.4). The 
results show that anxiety was the leading reason to prescribe BZDs. This was followed by 
insomnia and then by panic attack. Though less than 50% of the respondents indicated 
alcohol withdrawal and convulsive disorders as the indications for BZDs, they do occupy 
fourth and fifth place in the top five slots.    
Table 4.4 The descriptive statistics of reasons to prescribe BZDs by respondents  
Reasons for prescribing  Response: Yes (Count)  Response: Yes (Percent)  
1. Anxiety                               194 84.3
2. Insomnia                               169 73.5
3. Panic attacks                        146 63.5
4. Alcohol withdrawal              110 47.8
5. Convulsive disorders  
(ex: Seizures)  
104 45.2
6. Single-dose for phobia          91 39.6
7. Sedation                                88 38.3
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Reasons for prescribing  Response: Yes (Count)  Response: Yes (Percent)  
8. Grief reaction                78 33.9
9. Muscle relaxant   73 31.7
10. Movement disorders  55 23.9
11. Depression              25 10.9
12. Anti-vertigo                19 8.3
13. Bipolar disorder               19 8.3
14. Amnesic  12 5.2
15. Other(s) (please specify)  43 (Responded) 18.7
 
Note: 1. Sample Size N = 230 (3 missing responses). 2. Options were not mutually 
exclusive hence one prescriber could mark more than one response as his/her reason to 
prescribe BZDs.  
The following are responses recorded under the ‘other’ option : procedural sedation (16 
or 37.20%), adjunctive therapy to SSRI (4 or 9.30%), palliative care, restless leg 
syndrome and dementia associated agitation (3 responses or 6.97% each), travel and 
inherited patient (2 responses or 4.65% each), muscle contraction, dementia associated 
agitation, emergency use only, individual patient’s clinical response to drugs, anticipatory  
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nausea, part of medications for chronic pain, anti nausea, ventilator facilitation, spasticity, 
tinnitus, and finally, myoclonus (1 response or 2.32% each).  
 Significant results (Table 4.5) : Male physicians were more inclined to prescribe BZDs 
for single dose for phobia and sedation than their female equivalents.  
General practitioners and psychiatrists were more inclined to prescribe for muscle 
relaxant and bipolar disorders respectively.  
Physicians practicing for 0 to 19 years were more inclined to prescribe BZDs for 
insomnia than physicians practicing for 20 to 50 years. Physicians practicing for 20 to 50 
years were more inclined to prescribe BZDs as a muscle relaxant and for convulsive 
disorders.  
Physicians practicing in an area with more than 25,000 people were more inclined to 
prescribe for insomnia than physicians practicing in a less populated area. Physicians 
practicing in an area with less than 25,000 people were more inclined to prescribe for 
alcohol withdrawal, as muscle relaxants and for panic attacks.  
27 to 47 year old physicians were more predisposed to prescribing BZDs for depression 
than their older counterparts. 
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Table 4.5 The significant results from the chi-square analyses between demographic 
variables and the reasons for prescribing BZDs  
Reason for 
BZD 
prescription 
by 
physician(N) 
Demographic 
characteristic of 
physician (NN) 
% of NN 
= Yes’ 
Chi-square / 
Fisher’s 
exact  
p  Effect size= 
small/moderate 
/large 
Single dose 
for phobia 
(228)  
Male (145 ) 55.6 4.153 0.042 0.135 =small
  Female (83) 44.4      
Sedation 
(228) 
Male phys (145) 44.1 5.161 0.023 0.150 =small
  Female phys 
(83) 
28.9      
Muscle 
relaxant 
(140) 
General 
practitioners 
(129) 
41.1 0.004    
  Psychiatrist (11) 0      
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Reason for 
BZD 
prescription 
by 
physician(N) 
Demographic 
characteristic of 
physician (NN) 
% of NN 
= Yes’ 
Chi-square / 
Fisher’s 
exact  
p  Effect size= 
small/moderate 
/large 
Bipolar 
disorder 
(140) 
General 
practitioners 
(129) 
7.8 0.000    
  Psychiatrist (11) 54.5      
Insomnia 
(225) 
Phys with 20 to 
50 years of 
medical practice 
(119)  
68.1      
  Phys with 0 to 
19 years of 
medical practice 
(106)  
80.2 4.258 0.039 0.138 =small
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Reason for 
BZD 
prescription 
by 
physician(N) 
Demographic 
characteristic of 
physician (NN) 
% of NN 
= Yes’ 
Chi-square / 
Fisher’s 
exact  
p  Effect size= 
small/moderate 
/large 
Muscle 
relaxant 
(225) 
Phys with 20 to 
50 years of 
medical practice 
(119 ) 
38.7 4.446 0.035 0.141 =small
  Phys with 0 to 
19 years of 
medical practice 
(106 ) 
25.5      
Convulsive 
disorders 
(225) 
Phys with 20 to 
50 years of 
medical practice 
(119)  
52.9 6.620 0.010 0.172 =small
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Reason for 
BZD 
prescription 
by 
physician(N) 
Demographic 
characteristic of 
physician (NN) 
% of NN 
= Yes’ 
Chi-square / 
Fisher’s 
exact  
p  Effect size= 
small/moderate 
/large 
  Phys with 0 to 
19 years of 
medical practice 
(106)  
35.8      
Insomnia 
(226) 
Phys practicing 
in area with 
more than 25000 
people (128) 
80.6 4.550 0.033 0.142 =small
  Phys practicing 
in area less than 
25000 people 
(98) 
68      
85 
 
 
Reason for 
BZD 
prescription 
by 
physician(N) 
Demographic 
characteristic of 
physician (NN) 
% of NN 
= Yes’ 
Chi-square / 
Fisher’s 
exact  
p  Effect size= 
small/moderate 
/large 
Alcohol 
withdrawal 
(226) 
Phys practicing 
in area less than 
25000 people 
(98 )  
56.1 4.818 0.028 0.146 =small
  Phys practicing 
in area with 
more than 25000 
people (128) 
41.4      
Muscle 
relaxants 
(226) 
Phys practicing 
in area less than 
25000 people 
(98) 
41.5 7.195 0.007 0.178 =small
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Reason for 
BZD 
prescription 
by 
physician(N) 
Demographic 
characteristic of 
physician (NN) 
% of NN 
= Yes’ 
Chi-square / 
Fisher’s 
exact  
p  Effect size= 
small/moderate 
/large 
  Phys practicing 
in area with 
more than 25000 
people (128) 
25      
Panic attacks 
(226)  
Phys practicing 
in area less than 
25000 people 
(98) 
71.4      
  Phys practicing 
in area with 
more than 25000 
people (128) 
56.2 5.476 0.019 0.156 =small
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Reason for 
BZD 
prescription 
by 
physician(N) 
Demographic 
characteristic of 
physician (NN) 
% of NN 
= Yes’ 
Chi-square / 
Fisher’s 
exact  
p  Effect size= 
small/moderate 
/large 
Depression 
(207) 
Older (48 to 71 
years) phys 
(103) 
4.9      
  Younger (27 to 
47 years) phys 
(104) 
14.4 5.428 0.020 0.162 =small
 
Note: 1. The degree of freedom for all the reported results in table 4.5  is 1. 2. No effect 
size is calculated for results reporting Fisher’s exact test. 
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3. Reasons to prescribe BZDs beyond 90 days:   
Prescribers were asked to indicate the reason for prescribing BZDs beyond 90 days.  
‘Patient on long-term BZDs’ (chronic users) was the most cited reason for prescribing 
BZDs beyond 90 days. Furthermore, the extended prescribing was practiced in case the 
patient suffered from chronic anxiety, chronic insomnia, and if the patients were in 
palliative care. The results also show that 77.2% continue to prescribe BZDs after 90 
days (Table 4.6). 
 Table 4.6 The descriptive statistics of reasons to prescribe BZDs beyond 90 days by 
respondents 
Reasons to prescribe beyond 90 
days 
Response: Yes 
(Count)  
Response: Yes (Percent)  
1. Patient on long term BZDs  119 51.3
2. Chronic anxiety  116 50.0
3. Chronic insomnia                  86 37.1
4. Palliative care  68 29.3
5. Never  53 22.8
6. Convulsive disorders  48 20.7
7. No response to other medications  49 21.1
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Reasons to prescribe beyond 
90 days  
Response: Yes (Count)  Response: Yes (Percent)  
8. Chronic muscle spasms  34 14.7
9. Extended crisis in patient’s 
life    
31 13.4
10. Bipolar disorder  16 6.9
11. Other(s) (please specify)  29 (Responded) 12.9
 
Note: 1. Sample Size N = 232 (1 missing responses) 2. Options were not mutually 
exclusive hence one prescriber could mark more than one response as his/her reason to 
prescribe BZDs beyond 90 days.  
The other responses (n=29) were (Figure 4.6): inheriting patients who were either chronic 
users or unable to wean off BZDs (13 or 44.88%), dementia associated with agitation (2 
or 6.89%); restless leg syndrome (2 or 6.89%); panic attack prophylaxis if SSRIs are not 
helpful (1 or 3.45%); tinnitus (1 or 3.45%); continued ventilation (1 or 3.45%); anti- 
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spasticity agents (1 or 3.45%); adjunct to SSRI (1 or 3.45%); p r n  basis for insomnia (1 
or 3.45%); extended ICU admission (1 or 3.45%); movement disorders (1 or 3.45%); 
anticipatory nausea (chemotherapy related) (1 or 3.45%); and only when alternative 
groups have failed to achieve their effect (1 or 3.45%).  
   
 
Figure 4.6 Other reasons to prescribe BZDs beyond 90 days as stated by respondents  
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Significant results (Table 4.7):  
Psychiatrists were more inclined to prescribe BZDs for longer than 90 days for bipolar 
disorder than general practitioners.  
Physicians practicing for 20 to 50 years  were more inclined to cite “extended crises in 
person’s life”, “chronic muscle spasm” and “convulsive disorders” as a reason for 
prescribing BZDs for longer than 90 days. 
Older (48 to 71 years) physicians were more predisposed to citing “for extended crises in 
person’s life”, “chronic anxiety” and “convulsive disorders” as a reason for prescribing 
BZDs for more than 90 days.  
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 Table 4.7 The significant results from the chi-square analyses between demographic 
variables and the reasons for prescribing BZDs beyond 90 days 
Reason for BZD  
prescription by 
physician(N) 
 Demographic 
characteristic of 
physician (NN) 
% of NN 
= Yes’ 
Chi-
square / 
Fisher’s 
exact  
p  Effect size= 
small/moderate 
/large 
Bipolar disorder 
(140) 
General 
practitioners (129) 
8.5 0.018    
  Psychiatrist (11) 36.4      
Extended crises in 
person’s life (225) 
Phys with 20 to 
50 years of 
medical practice 
(118) 
17.8 4.278 0.039 0.138 =small 
  Phys with 0 to 19 
years of medical 
practice (107) 
8.4         
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Reason for BZD  
prescription by 
physician(N) 
 Demographic 
characteristic of 
physician (NN) 
% of NN 
= Yes’ 
Chi-
square / 
Fisher’s 
exact  
p  Effect size= 
small/moderate 
/large 
Chronic muscle 
spasm (225) 
Phys with 20 to 
50 years of 
medical practice 
(118) 
19.5 4.615 0.032 0.143 =small 
  Phys with 0 to 19 
years of medical 
practice (107) 
9.3      
Convulsive 
disorders (225) 
Phys with 20 to 
50 years of 
medical practice 
(118) 
29.7 11.554 0.001 0.227 =small 
  Phys with 0 to 19 
years of medical 
practice (107) 
11.2         
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Reason for BZD  
prescription by 
physician(N) 
 Demographic 
characteristic of 
physician (NN) 
% of NN 
= Yes’ 
Chi-
square / 
Fisher’s 
exact  
p  Effect size= 
small/moderate 
/large 
Extended crises in 
person’s life (207) 
Older (48 to 71 
years) phys (102) 
18.6 5.582 0.019 0.163 =small 
  Younger (27 to 47 
years) phys 105 
7.6      
Chronic anxiety 
(207) 
Older (48 to 71 
years) phys (102) 
59.8 8.117 0.004 0.198 =small 
  Younger (27 to 47 
years) phys (105)  
40      
Convulsive 
disorders (207) 
Older (48 to 71 
years) phys (102) 
30.4 8.850 0.003 0.207 =small 
  Younger (27 to 47 
years) phys (105)  
13.3      
 
Note 1. The degree of freedom for all the reported results in Table 4.7. is 1. 2. No effect 
size is calculated for results reporting Fisher’s exact test. 
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4.Concurrent prescription of more than one BZD:  
The WHO guidelines on BZDs explicitly state that no more than one BZD should be 
prescribed to the same patient. In spite of this recommendation, 17.9≈18.0% of the 
respondents concurrently prescribe more than one BZD to the same patient (Figure 4.7). 
 
Figure 4.7 Percent of respondents concurrently prescribing more than one BZD 
Note : Sample size N = 223 (10 missing)  
Of the 40 “yes” responses to the above question, only 36 mentioned the reason for 
prescribing more than one BZD concurrently to the same patient.  As seen below, the co-
morbidity of insomnia with anxiety was the principle indication for more than one BZD 
to the same patient (Table 4.8). 
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Table 4.8 The reasons to prescribe BZDs concurrently as stated by the respondents 
Reasons  Frequency  Percent  
Insomnia and Anxiety  11 30.6
To continue previous prescriptions  4 11.1
Additional PRN dose  2 5.6
Anxiety and Panic attacks  2 5.6
ICU setting  2 5.6
Long term use  2 5.6
Anxiety and Seizures  1 2.8
Chronic anxiety and Acute anxiety  1 2.8
Clona. for muscles ATIVAN for anxiety/insomnia  1 2.8
Insomnia and Panic  1 2.8
Insomnia and Panic attacks  1 2.8
No response to one BZD and other medications  1 2.8
Occ. when short term enhancement of effect required  1 2.8
Palliative setting  1 2.8
Patient specific reasons  1 2.8
Premed prior to intraprocedural sedation  1 2.8
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Reasons  Frequency Percent 
To continue previous precriptions; Unable to discontinue; Anxiety and 
Insomnia  
1 2.8 
Unable to discontinue one medication  1 2.8 
Use combination of Xanax and Ativan  1 2.8 
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5.Factors influencing BZD prescribing:  
The next question asked the prescribers to rate each of the 14 factors on the Likert scale 
of 1 (strongly disagree) to 7 (strongly agree).    
With respect to descriptive analysis, the mean was calculated for each variable. Table 4.9 
itemizes the results. 
Table 4.9 The mean of the responses indicated for factors influencing BZD prescribing 
Variable Mean 
Std. 
Deviation 
Interpretation 
Risk of abuse/ misuse 5.64 1.873 
6 
(Moderately agree) 
Effectiveness of drug 5.64 1.356 
6 
(Moderately agree) 
Indication 5.50 1.590 
6 
(Moderately agree) 
Side effects 5.22 1.567 
5 
(Agree) 
Drug interactions 4.89 1.744 
5 
(Agree) 
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Variable Mean 
Std. 
Deviation 
Interpretation 
Clinical practice 
guidelines 
4.66 1.766 
5 
(Agree) 
Continuing prescription 4.44 1.834 
4 
 (Neither Agree/Disagree) 
Availability of 
counseling 
4.01 1.951 
4 
(Neither Agree/Disagree) 
Affordability of 
counseling 
3.96 1.993 
4 
(Neither Agree/Disagree) 
Peer group 3.89 1.863 
4 
(Neither Agree/Disagree) 
Cost 3.84 1.809 
4 
(Neither Agree/Disagree) 
Drug availability 3.68 1.851 
4 
(Neither Agree/Disagree) 
Patient's request 3.59 1.753 
4 
(Neither Agree/Disagree) 
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Variable Mean 
Std. 
Deviation 
Interpretation 
Insurance coverage 3.49 1.914 
4 
(Neither Agree/Disagree) 
Manufacturer's 
information 
3.43 1.657 
3 
(Disagree) 
Pharmaceutical rep 2.65 1.602 
3 
(Disagree) 
 
Note: Sample size: 225 (missing responses were variable for each factor).  
The inferential analysis of the scale was conducted by collapsing the 3 levels of opinion 
(except level 4 which signifies neither agree nor disagree); i.e. 1 (strongly disagree), 2 
(moderately disagree) and 3 (disagree) into a one single opinion of disagreement. The 
levels for agreement (5, 6 and 7) were also recoded as a single opinion of agreement. This 
was done to simplify the presentation of results.  
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Significant results (Table 4. 10): Physicians practicing in group or multi-disciplinary unit 
were more inclined to mention “peer group” as a factor influencing their BZD prescribing 
than their counterparts who practiced alone. A greater percent of female physicians 
agreed with “clinical practice guidelines” influencing their BZD prescribing than their 
male equivalents. Physicians practicing in less populated area (less than 25,000 people) 
were more inclined to cite “availability of counseling” as a factor influencing their BZD 
prescribing than their counterparts in the areas which had 25,000 or more people.  
Table 4.10 The significant results from the chi-square analyses between demographic 
variables and factors influencing BZD prescribing 
Factor 
affecting 
BZD 
prescribing 
Demographic 
characteristic of 
physician (NN) 
% of 
NN = 
Yes’ 
Chi-square / 
Fisher’s 
exact  
p  Effect size= 
small/moderate 
/large 
Peer group 
(184) 
Phys practicing in 
group or multi-
disciplinary (158) 
50 12.094 0.002 0.256=small 
  Phys practicing 
alone (26) 
15.4       
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Factor 
affecting 
BZD 
prescribing 
Demographic 
characteristic of 
physician (NN) 
% of 
NN = 
Yes’ 
Chi-square / 
Fisher’s 
exact  
p  Effect size= 
small/moderate 
/large 
Clinical 
practice 
guidelines 
(215) 
Male (137) 49.6 6.276 0.043 0.171 =small 
  Female (78) 59       
Availability 
of counseling 
(204) 
Phys practicing in 
area with less than 
25000 people (89) 
57.3 6.465 0.039 0.178 =small 
  Phys practicing in 
area with equal or 
more than 25000 
people (115) 
40       
 
Note 1. The degree of freedom for all the reported results in Table 4.10 is 2. 2. No effect 
size is calculated for results reporting Fisher’s exact test. 
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6.Guidelines embraced by prescribers:  
Question 15 explored the usage of guidelines among the respondents. 51 (35.91%) of 142 
prescribers (91 missing responses) reported that they did not use guidelines. The 
respondents were supposed to give the name of guidelines employed, source of the same 
and their disagreement with the used guidelines for this question. 91 (64.10%) prescribers 
who gave a detailed response mentioned the name of the guideline issuing institution in 
place of actual title of the guideline hence the data analysis was performed combining 
both categories: name of guideline and source of guideline.  
Following are the major guidelines/sources of guidelines mentioned by the prescribers: 
Canadian Clinical Practice Guidelines (9.8%), Literature (9.2%), Canadian Medical 
Association (7.0%), Hospital/Administration (4.2%) and CME (4.2%), Canadian 
Anaesthesia Use Practice Guideline (2.8%), Canadian College of Family Physicians 
(2.8%), Canadian Psychiatric Association (2.8%), guidelines from medical school 
(2.8%), Canadian Journal Psychiatry (2.1%), Anxiety and Canadian Paediatric Society 
(2.1%). 1.2% responded by citing multiple sources (CMA, AMA, Canadian Psychiatric 
Association, American Psychiatric Association) and 1.4% cited CPSNL. The remaining 
guidelines/sources mentioned were AAFP, American Academy of Sleep Medicine, 
American Association of Paediatrics, CPA, Canadian Therapeutic Choice book,  
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CANMAT, CMHA, CPS & AAP, Critical Care Medicine, Manufacturer's info, Royal 
Australian College of GP, Tintanalli ER (0.7% each).  
 Following were the disagreement with the guidelines:  
1. “Corporate potential bias”  
2. “Sometimes lacks context”  
3. “I have my won rational approach to prescribing benzodiazepines”  
4. “differentiating efficacy of analgesia, sedatives and antipsychotics in given situations”  
5. “guidelines are guidelines, you are allowed not to follow them in all cases as this 
would be against guidelines”  
6. “guidelines not clear on pharmacotherapy for patients intolerant to or cannt (sic) afford 
first line drugs (SSRI, SNRI): benzodiazepines mentioned as long term adjunctive drugs”  
7. “Don't reflect reality of addiction”  
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7.Tools to optimize prescription standards:  
The second to last question looked at the perceptions of the prescribers with regards to 
the most helpful method/tool to optimize their prescribing standards (Table 4.11). 
61.5% of the respondents preferred to improve their prescribing standards by utilizing 
professional guidelines. CME by expert (44.1%) and availability and affordability of 
counseling (38.8%) were the second and third choices respectively for the same. The 
respondents did not regard regulation by the government as a helpful tool and 52.4% 
ranked it as an least helpful method to better their prescribing standard.  
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Table 4. 11  The perceptions of the prescribers with regards to the most helpful 
method/tool to optimize their prescribing standards 
Variable    
Most 
helpful (1)  
Moderately 
helpful (2)  
Somewhat 
helpful (3)  
Least 
helpful (4) 
Total  
Professional 
guidelines  
Frequency  107 43 18 6 174 
  Valid Percent 61.5 24.7 10.3 3.4 100.0 
CME by expert  Frequency  71 53 28 9 161 
  Valid Percent 44.1 32.9 17.4 5.6 100.0 
Regulation by 
government  
Frequency  12 16 32 66 126 
  Valid Percent 9.5 12.7 25.4 52.4 100.0 
Availability and 
affordability of 
counseling  
Frequency  59 21 38 34 152 
  Valid Percent 38.8 13.8 25 22.4 100.0
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8.Personal use of BZDs by prescribers:  
The last question pertained to the personal use of BZDs by the prescribers themselves. 
 
Figure 4.8 Personal use of BZDs by prescribers beyond 30/60/90 days.(Sample size: N: 
233) 
As seen in Figure 4.8, though a majority of respondents indicated that, personally, they 
would not use BZDs after 30, 60 and 90 days, 22.2 %, 18.1% and 15.7% were open to the 
consideration of  personally using BZDs after 30, 60 and 90 days respectively.  
 Significant results (Table 4.12):  
It was found that older (48 to 71 year) physicians were more open to using BZDs beyond 
60 days and 90 days. 
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Table 4.12 The significant results from the chi-square analyses between demographic 
variables and personal use of BZDs by the prescribers (respondents) 
Personal use 
of BZDs by 
physicians(N) 
 Demographic 
characteristic 
of physician 
(NN) 
% of 
NN = 
Yes’ 
Chi-square / 
Fisher’s exact 
p  Effect size= 
small/moderate /large 
Beyond 90 
days (194) 
Older phys (48 
to 71 year) (96) 
21.9 7.171 0.007 0.192 =small
  Younger phys 
(27 to 47) (98)  
8.2      
Beyond (60) 
days 194 
Older phys (48 
to 71 year) (96) 
22.9 4.696 0.030 0.156 =small
  Younger phys 
(27 to 47) (98) 
11.2      
 
Note: 1. The degree of freedom for all the reported results in Table 4.12 is 1. 2. No effect 
size is calculated for results reporting Fisher’s exact test. 
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Chapter 5: Discussion, Limitations, and Conclusions: 
This study is an effort to understand the BZD prescribing patterns of physicians as well 
as the variables which influence them. In this chapter I will discuss pertinent findings 
from the survey, enumerate limitations of the study as well as present conclusions for this 
study.  
 
Discussion:  
BZD prevalence is not uniform throughout Canada; provincial variations have been 
reported with Quebec being the highest consumer and Atlantic Canada (including 
Newfoundland and Labrador) being the lowest consumer of BZD (Hogan et al., 2003). 
Lorazepam was the most prescribed BZD in the present survey. In spite of regional 
variations observed by Hogan et al. (2003), this result is in tandem with the findings by 
Smith et al. (2008) who stated that in the Canadian province of Nova Scotia, lorazepam 
was the most commonly used BZD (though only among seniors and those persons 
receiving social security benefits). Furthermore, lorazepam was observed to be the drug 
(BZD) of choice for elderly patients in Quebec receiving a BZD prescription for the first 
time (Sylvestre et al., 2012). High potency BZDs such as lorazepam are associated with 
an increased risk of dependence (Nelson & Chouinard, 1999) and increased propensity to 
cause fall-related injuries among seniors (Sylvestre et al., 2012). As fall-related injuries 
may have implications for an individual (patient) and for society (cost of hospitalization  
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etc), the need for lorazepam prescriptions among the population, especially the elderly, 
should be evaluated via further research. In this survey, older physicians (48 to 71 years) 
were more inclined to prescribe chlordiazepoxide and flurazepam than their younger (27 
to 47 years old) counterparts. Flurazepam and chlordiazepoxide undergo both Phase I and 
Phase II metabolism and are considered long-acting BZDs. As Phase I metabolism slows 
with age, these BZDs are best avoided in the elderly (Nelson & Chouinard, 1999). 
Additionally, higher doses of flurazepam and chlordiazepoxide are associated with risks 
of injury among the elderly (Tamblyn, Abrahamowicz, Berger, McLeod, & Bartlett, 
2005). Furthermore, the guidelines do not recommend long-acting BZDs for patients 
aged 65 years and older (APA, 1990). As this survey did not link indications with the 
type (long- or short-acting) of BZDs prescribed, more research needs to be conducted to 
understand such prescriptions. 
This survey also revealed that a higher number of male physicians prescribed BZDs in 
comparison to female physicians. Despite the increase in the proportion of females 
joining the Canadian physician work force, male physicians still outnumber their female 
counterparts in clinical practice (CIHI, 2012). Furthermore gender bias was observed 
among the total number of respondents to this survey as only 36% of respondents were 
females. Both of these factors may explain the increased BZD prescribing by male 
physicians in Newfoundland and Labrador. The association between gender (male) and 
BZD prescribing was also reflected in a Norway based study by Bjørner and Lærum  
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(2003) which reported that male doctors were significantly associated with ‘high-volume’ 
BZD prescribing. It also reported that ‘high-volume’ prescribers consider BZDs a 
difficult class of medication to use in accordance with the current guidelines, and 
knowingly prescribe contrary to the current guidelines. Swedish physicians too had 
similar prescribing habits; a case study based survey which tested the significance 
between BZD prescribing habits and physician characteristics concluded that female 
physicians were significantly less likely to consider prescribing BZD for generalized 
anxiety syndrome than male physicians (Jarbrink, Carlsten, & Otto Frederiksen, 1999). 
Similarly, more number of male physicians were prescribing BZDs to patients than their 
female counterparts in British Columbia (Thomson & Smith, 1995). Another significant 
finding which demonstrated differing practices among male and female respondents to 
this survey is increased incidence of the prescribing of triazolam by male physicians. 
Triazolam, a short-acting BZD, is not recommended as a sedative-hypnotic since it 
causes  behavioural changes (Jensen & Regier, 2010). Increased reliance on 
pharmacotherapy as a treatment modality along with less time spent with the patient 
during consultation has been noted among Canadian psychiatrists (Garfinkel et  
al., 2004). The changing sex ratio among the Canadian physician workforce is being 
reflected by a continuing increase in the number of female physicians as general 
practitioners (CIHI, 2012). Hence, the translation of theory into practice is likely because, 
while respondents of both genders agreed with having CPG bearing upon their BZD  
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prescribing habits, female physicians were significantly more associated with perusing 
the guidelines in the BZD prescribing process than their male counterparts. Thus 
increased concordance with evidence-based medicine with respect to BZD prescribing 
may be expected at the primary care level. Though physicians agree with CPG being one 
of the determining factors in their prescribing of BZDs, in this survey, 77.2 % of 
physicians indicated prescribing BZDs for more than 90 days. Since the guidelines advise 
using BZDs for the shortest period of time possible and mention 2-4 weeks as an ideal 
period of time for its use, there is clearly a disjoint between clinical practice and 
guideline recommendations. Discordance between perceptions held by physicians and 
their clinical practice regarding BZD prescribing habits was also observed in an Irish 
survey. The evidence-based statement 'Low rate of benzodiazepine prescribing for 
prolonged periods (>2-4 weeks)'  was ranked third most important and relevant indicator 
of the physicians’ daily practice but a simultaneous prescription database audit proved 
otherwise; the majority of BZD prescriptions were for a duration of more than 4 weeks 
(Okechukwu, Benett, & Feely, 2006). Uptake of CPG has been the focus of many  
studies (Parker et al., 2008; Sekimoto, Imanaka, Kitano, Ishizaki, & Takahashi, 2006; 
Sinuff , Kahnamoui, Cook, & Giacomini, 2007). One such study (Parker et al., 2008) 
found comprehensiveness of the guidelines to be an important factor in its uptake by 
physicians, i.e. guidelines which do not include all the necessary treatment modalities for 
a disease state can face barriers to its use in clinical practice. In disease states such as  
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insomnia, psychological counselling or behavioural therapy is often required in addition 
to pharmacotherapy to achieve the desired outcome ( Jensen & Regier, 2010). 
Furthermore, physicians in the same study (Parker et al., 2008) were found to be reticent 
about using constantly revised guidelines since they feared that their clinical credibility 
would be threatened if they suggested frequent changes to the treatment modality of their 
patients. Also, since most guidelines are more than 2 pages in length, a shorter version 
may help improve its uptake. In this case, a recent Canadian study concluded that 
physicians were more enthusiastic to utilize a concise one-page guideline (Pimlott et al., 
2009).  Multifactorial intervention(s) aimed at not only prescribers (physicians primarily) 
but also patients and pharmacists and the simultaneous implementation of government 
legislation may be an answer to the dilemma of resistance to change in BZD prescribing 
habits of physicians. Two studies (Australian and Danish) were able to significantly 
reduce BZD usage in their respective regions using physician education (including 
provision of guidelines and motivational lectures), patient information campaigns 
involving local/regional media, government issued strictures on the length of BZD 
prescriptions, and mandatory in-person (and not telephonic) consultations to prescribe 
BZDs. Though the long-term impact of both these studies are not known, and the study 
by Dollman et al. (2005) focused on rural participants only, inclusion of the main  
stakeholders to modulate BZD prescribing may help optimize prescribing practices in 
Canada (Dollman et al., 2005; Jørgensen, 2007). In this survey, physicians have cited  
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‘professional guidelines’ as a variable which can help them optimise their BZD 
prescribing behaviour. A similar opinion is echoed in the study by Sinuff et al. (2007) 
which found that guidelines are viewed as a multipurpose instrument which can help 
make a clinical decision, improve knowledge about current practices, and can be used as 
an autonomy aid (to make independent decisions) in accordance with the professional 
stature of the respondents (physicians). While adoption of guidelines on BZDs were 
measured to be negligent in some studies, it was perceived to be adequate among 
Canadian physicians in 2001 (Neutel, Skurtveit, & Berg, 2012; Siriwardena et al., 2006; 
Svarstad & Mount, 2001; Tu, Mamdani, Hux, & Tu, 2001). However, the proposed 
conclusion by Tu et al. (2001) was refuted by an intervention study which concluded that 
guidelines had little effect on existing patterns of prescribing long-acting BZDs to seniors 
and the continuation of BZDs for long durations without any clinical evidence of 
effectiveness (Pimlott et al., 2003). The major limitation of these studies include  
conflation of the availability of guidelines  with awareness, adoption, and finally 
adherence of these guidelines. Development and publication of CPG are steps preceding 
its awareness, uptake, and finally, its continued adoption by clinicians. Accessibility and 
agreement with guidelines were cited as barriers to the use of sedation protocols among 
physicians practicing critical care medicine (Tanios, de Wit, Epstein, & Devlin, 2009 ).  
Incorporation of physician views to develop comprehensive guidelines which address 
management of non-clinical issues such as patient expectation may enhance the adoption  
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of a CPG. Time limitation is postulated to be an impediment in providing quality of care 
by physicians for patients with mental health issues. This concern can be alleviated by 
improved dissemination of BZD knowledge to the public to increase the awareness of 
clinical evidence on the prescribing and usage of medication for a correct length of time 
and indication(s). Also, a prescriber better equipped to identify mental health issues may 
be at an advantage through the utilization of a guideline recommended treatment 
algorithm (Smolders et al., 2010). 
 
In our survey ‘patient’s request’ as a variable influencing BZD prescribing received 
equivocal response from physicians. However, studies by Sekimoto et al. (2006) and 
Tracy, Coelho Dantas, & Upshur (2003) revealed that when faced with a trade-off 
between  satisfying their patients or limiting their prescriptions for genuine cases and 
stopping medication when it loses its effectiveness, physicians chose the former option. 
Tracy et al. (2003) further stated that physicians would change their common practice(s) 
in disease management to provide treatment which is deemed favourable by the patient.   
In the present survey, the primary reason to continue BZDs after 90 days was to continue 
longstanding prescriptions; also, respondents cited similar reasoning behind the decision 
to prescribe more than one BZD concurrently to the same patient. Discontinuation of 
BZDs in long-term users requires both patient and physician support. Records of Dutch 
patients who were long-term BZD users were assessed retrospectively after the  
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completion of a BZD discontinuation program. Only 12 % of patients were BZD free and 
the concurrent use of more than one BZD accounted for failure to discontinue the drug in 
33% of patients. While practice settings did not significantly affect continuation or 
resumption of BZD prescriptions, the authors surmised that patient pressure may have 
played a role in BZD prescribing patterns (Couvee, Timmermans, & Zitman, 2002). As 
noted in a Swedish qualitative study (Bendtsen, Hensing, McKenzie, & Stridsman, 1999) 
among general practitioners, the primary reason for patients to ask for BZDs is to 
continue their existing prescriptions. Swedish physicians reported that 37% of BZD users 
asking for prescriptions wanted to continue (and not start) their BZD consumption. These 
physicians cited anticipated refusal by elderly patients to discontinue  
BZDs and resistance to access specialized mental health services as barriers to the 
implementation of evidence-based prescribing practices. Conversely, 39% of Swedish 
general practitioners chose not to prescribe BZDs when faced with pressure from 
patients. 91% of these physicians noted abuse or risk of abuse as a factor in refusing to 
prescribe BZDs to patients in their daily practice. Risk of abuse was also one of the main 
variables that influenced the prescribing of BZDs among the respondents in the current 
survey. In the current climate of collaborative decision-making, patient perception and 
views are heavily weighed prior to deciding upon the clinical course of treatment. With 
respect to BZDs, (elderly) patients’ and physicians’ opinions of benefit-risk vary 
significantly; patients perceive BZDs as beneficial while physicians consider them as  
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risky long-term treatment for insomnia (Mah & Upshur, 2002). Patient education as a 
part of multifactorial intervention may be a viable option to reduce the prevalence of 
BZDs in the elderly population (Ostini, Jackson, Hegney, & Tett, 2011). A patient who is 
given the opportunity to compare his/her long held beliefs on the effectiveness of BZDs 
may revise them upon being presented with clinical evidence on the risks associated with 
its use (Martin, Tamblyn, Ahmed, & Tannenbaum, 2013).  
 
With respect to specialty, we found that a greater number of general practitioners (64%) 
indicated prescribing BZDs to their current patients. This may be due to the greater 
number of general practitioners than psychiatrists found in Newfoundland and Labrador 
(Canadian Medical Association, 2011). This result is echoed in a Swedish survey which 
concluded that psychiatrists prescribed less BZD than general practitioners (Jarbrink et 
al., 1999). However, a national prescription database study in Norway concluded that 
psychiatrists were contributing significantly more to the increased prevalence of BZD 
prescriptions in patients with insomnia (Hausken, Furu, Skurveit, Engeland, & Bramness, 
2009). General practitioners are the primary point of contact for people with mental as 
well as physical ailments, while psychiatrists focus upon diagnosing and treating the 
mental disorders. Therefore, this can translate into a high volume of BZD prescriptions 
by general practitioners as BZDs are indicated as anxiolytics, hypnotics, anticonvulsants,  
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amnestics, and myorelaxants.   Also many primary care physicians are averse to the idea 
of initiating BZD withdrawal in the elderly if they were unable to achieve success in their 
previous attempts and if the patients were chronic users (Cook, Marshall, Masci, & 
Coyne, 2007).  
 
This survey found that 18% of physicians were concurrently prescribing more than one 
BZD to the same patient. This result is substantiated by the findings of an office-based 
study which revealed that office-based psychiatrists were more likely to prescribe two or 
more sedative-hypnotics for anxiety disorders (Mojtabai & Olfson, 2010). The WHO 
guidelines (1996) explicitly state that more than one BZD should not be given to the 
same patient as they act on the same binding sites in the brain. The ‘65 years and over’ 
segment of the population is expected to increase in the coming years in Canada 
(Statistics Canada, 2007) and BZDs have been linked to falls and hip fractures in this 
aforementioned group (Cumming & Le Couteur, 2003). The current BZD prescribing 
trend needs to be corrected in the immediate future in order to avoid unnecessary 
medicating of patients, especially seniors.  
 
Zopiclone was rated as the second most frequent medication to be prescribed by the 
physicians in this survey. In Canada, zopiclone is considered a ‘good choice’ to manage 
insomnia because it is considered to have less side effects (tolerance). It is considered a  
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safer and effective alternative to BZDs with lesser chances for the occurrence of rebound 
insomnia as well as withdrawal symptoms (Jensen & Regier, 2010). Our results regarding 
zopiclone also complements the views of general practitioners in the UK who believe Z-
drugs to be a safer and, more effective class of medication (with fewer side effects) for 
insomnia in older patients (Siriwardena et al., 2006). 
 
A study in 2002 estimated  3.3 million Canadians aged 15 or older, or about one in every 
seven had insomnia (Statistics Canada, 2005). In this study, prescribing BZDs due to 
insomnia was significantly associated with physicians practicing in areas with more than 
25,000 people. This significant association may be on account of the high prevalence of 
insomnia in urban areas (Morin, LeBlanc, Daley, Gregoire, & Mérette, 2006). 
In my study, BZD prescriptions for panic disorders were significantly associated with 
physicians practicing in areas with less than 25,000 people, and ‘Availability of 
counseling’ was found to be a significant factor associated with physicians practicing in 
areas containing less than 25,000 people. Panic attacks can be managed with cognitive-
behavioral therapy which is considered efficacious during either acute or long-term 
treatment (Pollack et al., 2003). Non-pharmacological therapy such as cognitive 
behavioural therapy is postulated to be cost effective in international literature, though 
this finding is yet to be ascertained in a Canadian context (Myhr & Payne, 2006). 
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About 20% of the Canadian population, or around one-fifth of the older population, lives 
in rural areas (Statistics Canada, 2006 ; Havens, n.d.). Given that it is difficult to access 
health care (especially mental health specialists) in rural areas (Starkes, Poulin, & Kisely, 
2005), the optimization of BZD prescribing may be greatly assisted if relevant resources 
(such as certified counsellors, counselling centres etc) were provided to them. 
Additionally, health care education aimed at the public with less education may help 
improve their usage of such services as increased utilization of specialized mental health 
facilities was associated with better educated patients within Atlantic Canada (Starkes et 
al., 2005). 
 
The adverse effects resulting from acute as well as chronic use of BZDs are well-known 
to prescribers due their educational background, clinical experience and constant 
exposure to the sources of CME. Hence, it was perplexing to note that around 22.2 % of 
the prescribers were open to the consideration of personally using BZDs after 30 or more 
days. A study focused upon exploring medication use among Swiss physicians reported 
similar findings: it revealed that self- medication among physicians 
 was more common for tranquilizers including hypnotics and less frequent in case of 
antidepressant drugs (Schneider, Gallacchi, Goehring, Künzi, & Bovier, 2007). Though 
the same study (Schneider et al., 2007) reported self-medication to be more among 
younger physicians, we found that older physicians were significantly more inclined to  
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self-medicate with BZDs for more than 60 or 90 days. The following factors (combined 
or individually) may explain the personal use of BZDs among older physicians: impaired  
mental and/ or physical health, a tendency to  treat themselves i.e. self-referral (Töyry et 
al., 2000) and fewer barriers to procure medication. Furthermore, a prescribing pattern of 
sedative hypnotics for patients is found to have a significant association with the self-
medicating behaviour of older physicians (Verger et al., 2004) because high volume BZD 
prescribing in their practice is correlated to increased personal use.  Note that there may 
be other individual factors which contribute to self-medication, though literature on the 
subject is limited. Education regarding self-treatment (including self-medication), 
information on the BZD class of drugs and interventions to diminish the threshold for 
seeking counsel from health care providers may help reduce personal usage of BZDs. 
Limitations:  
This is a cross-sectional survey. No causal inference could be drawn from its results, only 
associations between factors can be concluded. 
Given the methodology, bias is introduced through the limitations of informational recall 
via memory. 
Physicians practicing for 20 to 50 years as well as older (48 to 71 years) physicians were 
more inclined to cite ‘extended crises in person’s life’ as a reason for prescribing BZDs 
for longer than 90 days. Though this was a much cited opinion, it is also subjective in  
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nature.Therefore, it was difficult to draw a definite conclusion from it. Further research 
may need to be conducted to understand the precise definition of this phrase from the 
physician’s viewpoint. 
Research which focuses on the reasons and variables that account for personal use of 
BZDs by physicians and the questions related to BZD prescribing with respect to each 
segment of the population (age –wise) may provide us with more information on BZD 
prescribing patterns.  
Online resources (such as web-based questionnaires) were not explored to seek responses 
for this survey. 
 
Conclusions: 
The prescribing patterns of BZDs vary. Gender-based variations were observed; female 
physicians are more inclined towards uptake of CPG. Male physicians were significantly 
associated with more BZD prescribing among Newfoundland and Labrador physicians; 
this may be attributed to the increased male presence in the Canadian physician work 
force. These practice patterns may have implications in the primary care setting due to 
the increasing feminization of the Canadian physician workforce (especially in 
family/general practice). 
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In this survey, discordance between agreement with the recommendations of the CPG 
and its implementation in the clinical practice was observed. Barriers to the adoption and 
adherence of the CPG need to be addressed. Continuation of long-term prescriptions as a 
reason to further prescribe BZDs was identified as a common theme behind inappropriate 
prescriptions. Patient pressure or their expectations may be one of the factors behind such 
clinical decisions. Improving public awareness on the benefits-risks of taking BZDs for 
short- and long-term durations may help remodel patient views on BZDs. Furthermore, 
implementation of multipronged interventions involving all stakeholders such as 
physicians, patients, health care organizations as well as federal/ provincial regulatory 
bodies may decrease the inappropriate prescribing of BZDs by physicians. 
Older physicians significantly prescribe more chlordiazepoxide and flurazepam to their 
patients; both these agents  are associated with risk of injury among the elderly 
population. As the proportion of the senior population is growing at a faster rate in the 
developed world, geriatric medicine needs to evolve and involve physicians to ensure 
harm reduction due to inappropriate medications. Additionally, general practitioners were 
more likely to prescribe BZDs than psychiatrists. Given that primary care physicians are 
the first point of contact (for patients) in the health care setup, the initiation or 
continuation of BZD prescriptions by general practitioners is concerning. Informational  
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or training modules addressing the educational needs of  general practitioners in both 
urban and rural areas may help remedy the situation. Further research needs to be carried 
out to link each prescribed BZD with its indication(s) to understand the reasoning behind 
such prescriptions. 
Lastly, personal use of BZDs beyond the recommended period of time by physicians may 
be due to self-referral and perceived benefits of the drug. Older physicians were 
significantly more prepared to take BZDs for long-term use. Personal choices of 
physicians in disease management may have an impact on their work place functioning. 
Thus, an assessment of the health beliefs held by older physicians may help elucidate the 
factors affecting their personal preferences of treatment algorithms.  
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APPENDIX A: COVER LETTER FOR FIRST CONTACT 
  
 
Faculty of Medicine 
 
Clinical Epidemiology Unit 
300 Prince Philip Drive, Health Sciences Centre 
St. John’s, NL  Canada  A1B 3V6 
Tel: 709-777- 7390/7346:  Fax: 709-777-7877  
www.med.mun.ca/graduate/pages/epidemiology.htm   
 
June 4, 2007 
 
 
Dear Doctor:  
 
As you are aware, benzodiazepines are a class of drugs that have a wide range of actions 
including, but not limited to, anxiolytic, hypnotic, anticonvulsant, amnesic, and myorelaxant. 
  
In 2002, a team of concerned physicians, academics, allied health professionals, private and 
public insurers, government agencies, and concerned citizens formed an organization to 
evaluate prescribing and usage patterns of benzodiazepines.  Initially, a Canada /United States 
collaboration, the organization has grown significantly in the past few years, and now has an 
international membership.  
 
At this time we are soliciting your help to evaluate current benzodiazepine prescribing patterns 
as well as factors that may be influencing benzodiazepine prescribing.  Through your efforts, 
we hope to increase our understanding of how benzodiazepines are prescribed and eventually 
make available evidence based guidelines. 
 
The accompanying questionnaire is voluntary and can be completed in approximately 10 
minutes. Though every effort is made to ensure the anonymity of the accompanying 
questionnaire, it can not be guaranteed.  The numeric code on the return envelope is only to 
identify non-respondents so that a reminder can be sent. The code will not be linked to the 
responses.  We understand that your time is valuable and would like to thank you, in 
advance, for your contribution to this timely and important research. 
 
Please return the completed questionnaire in the postage-paid pre-addressed envelope by  
June 30.  Return of the questionnaire will serve as your consent to participate in this study. 
 
If you would like to discuss the study further, please do not hesitate to contact Dr Gerry 
Mugford (gmugford@mun.ca ; tel. (709) 777-7390 / pager (709) 570-9090) or Shweta Pai 
(k42ssp@mun.ca ; tel. (709) 777-6305).  
 
Sincerely, 
 
 
Dr. Gerry Mugford        Ms. Shweta Pai 
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APPENDIX B: COVER LETTER FOR SECOND CONTACT 
 
Faculty of Medicine 
 
Clinical Epidemiology Unit 
300 Prince Philip Drive, Health Sciences Centre 
St. John’s, NL  Canada  A1B 3V6 
Tel: 709-777- 7390/7346:  Fax: 709-777-7877  
www.med.mun.ca/graduate/pages/epidemiology.htm   
 
July 16, 2007 
 
Dear Doctor:  
 
As you are aware, benzodiazepines are a class of drugs that have a wide range of actions 
including, but not limited to, anxiolytic, hypnotic, anticonvulsant, amnesic, and myorelaxant. 
  
In 2002, a team of concerned physicians, academics, allied health professionals, private and 
public insurers, government agencies, and concerned citizens formed an organization to 
evaluate prescribing and usage patterns of benzodiazepines. Initially, a Canada /United States 
collaboration, the organization has grown significantly in the past few years, and now has an 
international membership.  
 
At this time we are soliciting your help to evaluate current benzodiazepine prescribing patterns 
as well as factors that may be influencing benzodiazepine prescribing. Through your efforts, 
we hope to increase our understanding of how benzodiazepines are prescribed and eventually 
make available evidence based guidelines. A copy of the enclosed questionnaire was 
previously mailed to you; however we have not yet received your response. If you have 
returned your questionnaire please accept our sincere thanks and disregard this 
correspondence.  If not, please take a few moments to complete the enclosed replacement 
questionnaire and return it in the postage-paid pre-addressed envelope. Please return the 
completed questionnaire by August 16.  
 
The accompanying questionnaire is voluntary and can be completed in approximately 10 
minutes. Return of the questionnaire will serve as your consent to participate in this study. 
Though every effort is made to ensure the anonymity of the accompanying questionnaire, it can 
not be guaranteed.  
 
We understand that your time is valuable and would like to thank you, in advance, for 
your contribution to this timely and important research. 
 
If you would like to discuss the study further, please do not hesitate to contact Dr Gerry 
Mugford (gmugford@mun.ca ; tel. (709) 777-7390 / pager (709) 570-9090) or Shweta Pai 
(k42ssp@mun.ca ; tel. (709) 777-6305).  
 
Sincerely, 
Dr .Gerry Mugford                    Ms. Shweta Pai 
 
Dr. Terrence Callanan    151 
APPENDIX C: SURVEY QUESTIONNAIRE: A survey assessing current benzodiazepine prescribing 
patterns and factors influencing benzodiazepine prescribing  in Newfoundland and Labrador physicians                  
SECTION I: Q 1 to Q 9 
 
Q1. Your gender (Place a √ in the appropriate 
box) 
□  Male    □  Female  
 
Q2. Your present age  
 
 
 
Q3. Year you completed medical studies  
 
YYYY 
 
Q4. How many years have you practiced 
medicine? 
 
 
Q5. Population of the community where you 
practice? (Place a √ in the appropriate box) 
□  Less than 2,000    
□  2,000-4,999    
□  5,000-9,999    
□  10,000-24,999    
□  25,000-49,999    
□  50,000-99,999    
□  100,000 or more   
 
 
Q6. Your practice is best described as (Place a 
√ in the appropriate box) 
□  Office practice  
□  Hospital based    
□  Public clinic    
 
Q7. You (Place a √ in the appropriate box) 
□  Practice alone    
□  Practice in a group (all physicians) 
□  Practice as part of a multidisciplinary team 
 
Q8. Which best describes you?  (Place a √ in 
the appropriate box) 
□  General practitioner   
□  Child psychiatrist   
□  Adult psychiatrist   
□  Forensic psychiatrist   
□  Neurologist     
□  Other (please specify) 
___________________ 
 
Q9. Do you currently prescribe 
benzodiazepines? (Place a √ in the appropriate 
box) 
□  Yes (Please continue to Q 10) 
□  No (Please stop here. Thank you for your 
support.)
SECTION II: Q 10 to Q 17 
 
Q10. From the list below, please indicate the drugs you currently prescribe (Circle all that apply) 
 
1. Alprazolam (e. g.: Xanax®)                    
2. Bromazepam ( Lectopam®)            
3. Chlordiazepoxide ( Apo-Chlordiazepoxide®)            
4. Clobazam  ( Frisium®)                   
5. Clonazepam (Rivotril®)                 
6. Clorazepate (Novo-Clopate®)       
7. Diazepam (Valium®)                    
8. Estazolam ( ProSom®)                  
9. Flurazepam ( Dalmane®)              
10. Lorazepam (Ativan®)   
11. Midazolam ( Apo-Midazolam Injectable®) 
 
12. Nitrazepam (Mogadon®)             
13. Oxazepam (Apo-Oxazepam®)     
14. Quazepam (Doral®)                     
15. Temazepam (Restoril®)               
16. Triazolam ( Halcion®)                 
17. Zaleplon (Starnoc®)                    
18. Zopiclone (Imovane®)                
19. Zolpidem (Ambien®) 
20. Carisoprodol (Soma®)                   
21. Other(s) (please specify) 
___________________________ 
 
Q11. Please indicate your reason(s) for prescribing benzodiazepines (Circle all that apply). 
1. Anxiety           
2. Insomnia            
3. Depression                                   
4. Movement disorders                      
5. Alcohol withdrawal                         
6. Muscle relaxant               
7. Grief reaction    
8. Single-dose for phobia          
9. Convulsive disorders (ex: Seizures)  
10. Anti-Vertigo                                   
11. Sedation                    
12. Panic attacks            
13. Amnesic  
14. Bipolar disorder   
15. Other(s) (please specify) 
___________________________ 
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Q 12. Please indicate your reason(s) to continue benzodiazepines beyond 90 days (Circle all that 
apply). 
1. Never         
2. Extended crisis in patient’s life               
3. Chronic insomnia                   
4. Chronic anxiety   
5. Palliative care                            
6. No response to other medications 
 
7. Chronic muscle spasms 
8. Convulsive disorders 
9. Bipolar disorder 
10. Patient on long term benzodiazepine                      
11. Other(s) (please specify) 
____________________________
 
Q13a. Do you prescribe more than one benzodiazepine concurrently to the same patient : Y/ N 
 
Q13b. If ‘Yes’ to Q 13a then please specify the reason(s) for prescribing more than one 
benzodiazepine concurrently: 
  
 
Q14. Please indicate the degree to which the following variables influence your benzodiazepine 
prescribing habits. (Please circle the appropriate number) 
           
           Variable                                    Strongly                       Neither Agree/                       Strongly  
                                                                 Disagree                            Disagree                              Agree 
1. Clinical practice guidelines                1 2 3 4 5 6 7 
2. Peer Group                  1 2 3 4 5 6 7 
3. Side effects                  1 2 3 4 5 6 7 
4. Drug interactions                 1 2 3 4 5 6 7 
5. Insurance coverage                 1 2 3 4 5 6 7 
6. Drug availability                 1 2 3 4 5 6 7 
7.  Cost                                                           1 2 3 4 5 6 7 
8. Risk of abuse/misuse                              1 2 3 4 5 6 7 
9. Manufacturers’ information                        1  2 3 4 5 6 7 
10. Pharmaceutical rep                                    1 2 3 4 5 6 7 
11. Patients’ request                                        1 2 3 4 5 6 7 
12. Indication                               1 2 3 4 5 6 7 
13. Effectiveness of drug                                1 2 3 4 5 6 7 
14. Continuing an existing prescription          1 2 3 4 5 6 7 
15. Availability of counseling                         1 2 3 4 5 6 7 
16. Affordability of counseling                       1 2 3 4 5 6 7 
17. Other(s) (please list):______________    1            2             3            4             5            6            7 
 
 
Q15. In Q14 above you have indicated the degree to which practice guidelines influence your 
benzodiazepine prescribing patterns. Could you please indicate: 
1 Which guidelines do you use? _________________________________  
2 Who provides them? _________________________________________ 
3 Disagreements with these guidelines. (If any) 
________________________________________________________________ 
 
Q16. Please indicate which of the following would most help you to optimize your benzodiazepine 
prescribing. (Please rank them 1(most helpful), 2, 3, 4(least helpful) : 
 Professional guidelines     CME by an expert in the field      Regulation/Law by the government 
 Availability and affordability of counseling based treatments for anxiety disorders  Other (please 
specify): _______________________ 
 
Q17. Please indicate whether you would personally use benzodiazepines beyond: a. 30 days (Y/N)     
b. 60 days (Y/N)     c.  90 days (Y/N). 
Thank you 
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